<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'><collection><source>PubTator</source><date></date><key>BioC.key</key><document><id>9811075</id><passage><infon key="name_3">surname:Boon;given-names:Laurence M</infon><infon key="name_2">surname:Prescott;given-names:Trine</infon><infon key="name_1">surname:Brouillard;given-names:Pascal</infon><infon key="name_0">surname:Smeland;given-names:Marie F.</infon><infon key="fpage">57</infon><infon key="issue">1</infon><infon key="year">2021</infon><infon key="article-id_publisher-id">jmedgenet-2021-108179</infon><infon key="article-id_doi">10.1136/jmedgenet-2021-108179</infon><infon key="type">front</infon><infon key="volume">60</infon><infon key="license">This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.</infon><infon key="section_type">TITLE</infon><infon key="kwd">genetics medical loss of function mutation female urogenital diseases and pregnancy complications</infon><infon key="name_8">surname:Vikkula;given-names:Miikka</infon><infon key="name_7">surname:Holla;given-names:Oystein L.</infon><infon key="lpage">64</infon><infon key="name_6">surname:Nystad;given-names:Mona</infon><infon key="name_5">surname:Nordbakken;given-names:Cecilie V</infon><infon key="name_4">surname:Hvingel;given-names:Bodil</infon><infon key="article-id_pmc">9811075</infon><infon key="article-id_pmid">34876502</infon><offset>0</offset><text>Biallelic ANGPT2 loss-of-function causes severe early-onset non-immune hydrops fetalis</text><annotation id="20233"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="10" length="6" /><text>ANGPT2</text></annotation><annotation id="20234"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="71" length="15" /><text>hydrops fetalis</text></annotation></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>87</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>98</offset><text>Hydrops fetalis, a pathological fluid accumulation in two or more body compartments, is aetiologically heterogeneous. We investigated a consanguineous family with recurrent pregnancy loss due to severe early-onset non-immune hydrops fetalis.</text><annotation id="20235"><infon key="identifier">MESH:D000022</infon><infon key="type">Disease</infon><location offset="271" length="14" /><text>pregnancy loss</text></annotation><annotation id="20236"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="323" length="15" /><text>hydrops fetalis</text></annotation><annotation id="20237"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="98" length="15" /><text>Hydrops fetalis</text></annotation></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>340</offset><text>Methods and results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>360</offset><text>Whole exome sequencing in four fetuses with hydrops fetalis revealed that they were homozygous for the angiopoietin-2 (ANGPT2) variant Chr8 (GRCh37/Hg19): 6385085T&gt;C, NM_001147.2:c.557A&gt;G. The substitution introduces a cryptic, exonic splice site predicted to result in loss of 10 nucleotides with subsequent shift in reading frame, leading to a premature stop codon. RNA analysis in the heterozygous parents demonstrated loss of detectable mutant allele, indicative of loss-of-function via nonsense-mediated mRNA decay. Serum ANGPT2 levels were reduced in the parents. In a pregnancy with a healthy, heterozygous child, transiently increased fetal nuchal translucency was noted.</text><annotation id="20238"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="463" length="14" /><text>angiopoietin-2</text></annotation><annotation id="20239"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="479" length="6" /><text>ANGPT2</text></annotation><annotation id="20240"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="887" length="6" /><text>ANGPT2</text></annotation><annotation id="20241"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="539" length="8" /><text>c.557A&gt;G</text></annotation><annotation id="20242"><infon key="identifier">tmVar:g|SUB|T|6385085|C;HGVS:g.6385085T&gt;C;VariantGroup:22;CorrespondingGene:285;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="515" length="10" /><text>6385085T&gt;C</text></annotation><annotation id="20243"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="404" length="15" /><text>hydrops fetalis</text></annotation><annotation id="20244"><infon key="type">Species</infon><location offset="527" length="11" /><text>NM_001147.2</text></annotation></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1040</offset><text>Conclusion</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1051</offset><text>Pathogenic heterozygous ANGPT2 missense variants were recently shown to cause autosomal dominant primary lymphoedema. ANGPT2 is a ligand of the TIE1-TIE2 (tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 1 and 2) pathway. It is critical to the formation and remodelling of blood and lymphatic vessels and is involved in vessel maintenance. ANGPT2 knockout mice die from generalised lymphatic dysfunction. We show here that a homozygous pathogenic variant causes loss-of-function and results in severe early-onset hydrops fetalis. This is the first report of an autosomal recessive ANGPT2-related disorder in humans.</text><annotation id="20245"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="1075" length="6" /><text>ANGPT2</text></annotation><annotation id="20246"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="1169" length="6" /><text>ANGPT2</text></annotation><annotation id="20247"><infon key="identifier">7075</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3957</infon><location offset="1195" length="4" /><text>TIE1</text></annotation><annotation id="20248"><infon key="identifier">7010</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="1200" length="4" /><text>TIE2</text></annotation><annotation id="20249"><infon key="identifier">7294</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2497</infon><location offset="1206" length="15" /><text>tyrosine kinase</text></annotation><annotation id="20250"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="1424" length="6" /><text>ANGPT2</text></annotation><annotation id="20251"><infon key="identifier">MESH:D008206</infon><infon key="type">Disease</infon><location offset="1466" length="21" /><text>lymphatic dysfunction</text></annotation><annotation id="20252"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="1597" length="15" /><text>hydrops fetalis</text></annotation><annotation id="20253"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="1692" length="6" /><text>humans</text></annotation><annotation id="20254"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="1440" length="4" /><text>mice</text></annotation><annotation id="20255"><infon key="identifier">MESH:D010538</infon><infon key="type">Disease</infon><location offset="1148" length="19" /><text>primary lymphoedema</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1700</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1713</offset><text>Hydrops fetalis is a pathological accumulation of fluid in two or more body compartments. This aetiologically heterogeneous condition is caused by increased interstitial fluid production or decreased lymphatic return, and may result in increased nuchal translucency, lymphatic malformations (eg, cystic hygroma), subcutaneous fluid accumulation, pleural/pericardial effusion, ascites and placental thickening.</text><annotation id="20256"><infon key="identifier">MESH:D018191</infon><infon key="type">Disease</infon><location offset="2009" length="14" /><text>cystic hygroma</text></annotation><annotation id="20257"><infon key="identifier">MESH:D001201</infon><infon key="type">Disease</infon><location offset="2089" length="7" /><text>ascites</text></annotation><annotation id="20258"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="1713" length="15" /><text>Hydrops fetalis</text></annotation><annotation id="20259"><infon key="identifier">MESH:D010996</infon><infon key="type">Disease</infon><location offset="2059" length="28" /><text>pleural/pericardial effusion</text></annotation><annotation id="20260"><infon key="identifier">MESH:D008209</infon><infon key="type">Disease</infon><location offset="1980" length="23" /><text>lymphatic malformations</text></annotation><annotation id="20261"><infon key="identifier">MESH:D010922</infon><infon key="type">Disease</infon><location offset="2101" length="20" /><text>placental thickening</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2123</offset><text>Historically, red cell allo-immunisation was the major cause of hydrops fetalis. Today, non-immune hydrops fetalis (NIHF; Mendelian Inheritance in Man, MIM: 236750) constitutes approximately 90% of cases. The estimated prevalence of hydrops fetalis ranges from 1:1500 to 1:4000 births. Early onset and aetiology are prognostic predictors in NIHF. Presentation in the first trimester increases the likelihood of a fetal aneuploidy. In a prenatal series of more than 12 000 pregnancies, almost half of 66 NIHF cases were attributed to a chromosomal abnormality. Aneuploidy conferred an extremely poor prognosis. In liveborn infants with NIHF, neonatal mortality is as high as 60%. </text><annotation id="20262"><infon key="identifier">MESH:D000782</infon><infon key="type">Disease</infon><location offset="2683" length="10" /><text>Aneuploidy</text></annotation><annotation id="20263"><infon key="identifier">MESH:D030342</infon><infon key="type">Disease</infon><location offset="2245" length="28" /><text>Mendelian Inheritance in Man</text></annotation><annotation id="20264"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="2626" length="4" /><text>NIHF</text></annotation><annotation id="20265"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="2356" length="15" /><text>hydrops fetalis</text></annotation><annotation id="20266"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="2211" length="26" /><text>non-immune hydrops fetalis</text></annotation><annotation id="20267"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="2758" length="4" /><text>NIHF</text></annotation><annotation id="20268"><infon key="identifier">MESH:D000782</infon><infon key="type">Disease</infon><location offset="2542" length="10" /><text>aneuploidy</text></annotation><annotation id="20269"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="2464" length="4" /><text>NIHF</text></annotation><annotation id="20270"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="2239" length="4" /><text>NIHF</text></annotation><annotation id="20271"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="2187" length="15" /><text>hydrops fetalis</text></annotation><annotation id="20272"><infon key="identifier">MESH:D002869</infon><infon key="type">Disease</infon><location offset="2658" length="23" /><text>chromosomal abnormality</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2805</offset><text>Bellini et al  presented a classification scheme for NIHF based on underlying mechanism, including chromosomal imbalance, infection, placental abnormality, twin-to-twin transfusion, cardiovascular disorders, syndromes and lymphatic dysplasia. In an update, they classified 19.8% of cases as idiopathic. In a recent review including only cases meeting the strict criteria for NIHF, the aetiology was identified in 86.3%. The most prevalent aetiologies in the study by Laterre et al  were chromosomal imbalance (33 of 102; 32.4%), lymphatic dysplasia (14 of 102; 13.7%) and cardiovascular disorders (10 of 102; 9.8%). The authors also developed a flow chart outlining a systematic diagnostic approach that emphasises the importance of next-generation sequencing (NGS). </text><annotation id="20273"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="2987" length="24" /><text>cardiovascular disorders</text></annotation><annotation id="20274"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="2858" length="4" /><text>NIHF</text></annotation><annotation id="20275"><infon key="identifier">MESH:D025063</infon><infon key="type">Disease</infon><location offset="3292" length="21" /><text>chromosomal imbalance</text></annotation><annotation id="20276"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="2927" length="9" /><text>infection</text></annotation><annotation id="20277"><infon key="identifier">MESH:D002318</infon><infon key="type">Disease</infon><location offset="3377" length="24" /><text>cardiovascular disorders</text></annotation><annotation id="20278"><infon key="identifier">MESH:C537255</infon><infon key="type">Disease</infon><location offset="3334" length="19" /><text>lymphatic dysplasia</text></annotation><annotation id="20279"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="3180" length="4" /><text>NIHF</text></annotation><annotation id="20280"><infon key="identifier">MESH:D025063</infon><infon key="type">Disease</infon><location offset="2904" length="21" /><text>chromosomal imbalance</text></annotation><annotation id="20281"><infon key="identifier">MESH:D010922</infon><infon key="type">Disease</infon><location offset="2938" length="21" /><text>placental abnormality</text></annotation><annotation id="20282"><infon key="identifier">MESH:C537255</infon><infon key="type">Disease</infon><location offset="3027" length="19" /><text>lymphatic dysplasia</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3573</offset><text>In a series of 127 cases of prenatally diagnosed NIHF, which were aetiologically unresolved by standard analyses, a genetic cause was detected in 29% by whole exome sequencing (WES). A comprehensive systematic review of monogenic causes of NIHF identified 517 candidate genes, including 177 for which evidence was strong or emerging. Of these 177, 5.1% were lymphatic-related genes. Autosomal recessive inheritance was the most frequent (61.8%) when aetiology was known, although all Mendelian modes of inheritance were represented. </text><annotation id="20283"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="3813" length="4" /><text>NIHF</text></annotation><annotation id="20284"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="3622" length="4" /><text>NIHF</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4107</offset><text>NIHF due to lymphatic abnormalities is a form of generalised lymphatic dysplasia, a subgroup of primary lymphoedema. In Genomics England's PanelApp, evidence of an association between pathogenic variants in 40 genes and primary lymphoedema is strong ('green' category genes; panel version: 2.12, 13 March 2021). For fetal hydrops (panel version 1.25, 13 March 2021), the evidence for causation is strong for 56 genes. The two panels overlap with 19 genes.</text><annotation id="20285"><infon key="identifier">MESH:D010538</infon><infon key="type">Disease</infon><location offset="4327" length="19" /><text>primary lymphoedema</text></annotation><annotation id="20286"><infon key="identifier">MESH:D010538</infon><infon key="type">Disease</infon><location offset="4203" length="19" /><text>primary lymphoedema</text></annotation><annotation id="20287"><infon key="identifier">MESH:C537255</infon><infon key="type">Disease</infon><location offset="4168" length="19" /><text>lymphatic dysplasia</text></annotation><annotation id="20288"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="4107" length="4" /><text>NIHF</text></annotation><annotation id="20289"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="4423" length="13" /><text>fetal hydrops</text></annotation><annotation id="20290"><infon key="identifier">MESH:D044148</infon><infon key="type">Disease</infon><location offset="4119" length="23" /><text>lymphatic abnormalities</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4569</offset><text>Subsequent to the original publication of primary lymphoedema involving the vascular endothelial growth factor 3 gene (VEGFR3, encoded by the FLT4 gene), the central role of VEGFR3 in signalling was identified. Genes more recently added to the pathway include ADAMTS3, FBXL7  and ARAF.  New pathways involving lymphangiogenesis and remodelling have also been identified and involve genes such as PIEZO1, EPHB4, CALCR  and GDF2. </text><annotation id="20291"><infon key="identifier">2324</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7321</infon><location offset="4688" length="6" /><text>VEGFR3</text></annotation><annotation id="20292"><infon key="identifier">2324</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7321</infon><location offset="4711" length="4" /><text>FLT4</text></annotation><annotation id="20293"><infon key="identifier">2324</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7321</infon><location offset="4743" length="6" /><text>VEGFR3</text></annotation><annotation id="20294"><infon key="identifier">9508</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8596</infon><location offset="4829" length="7" /><text>ADAMTS3</text></annotation><annotation id="20295"><infon key="identifier">23194</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">69121</infon><location offset="4838" length="5" /><text>FBXL7</text></annotation><annotation id="20296"><infon key="identifier">369</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1249</infon><location offset="4849" length="4" /><text>ARAF</text></annotation><annotation id="20297"><infon key="identifier">9780</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">124356</infon><location offset="4965" length="6" /><text>PIEZO1</text></annotation><annotation id="20298"><infon key="identifier">2050</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20939</infon><location offset="4973" length="5" /><text>EPHB4</text></annotation><annotation id="20299"><infon key="identifier">799</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1320</infon><location offset="4980" length="5" /><text>CALCR</text></annotation><annotation id="20300"><infon key="identifier">2658</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">32299</infon><location offset="4991" length="4" /><text>GDF2</text></annotation><annotation id="20301"><infon key="identifier">MESH:D010538</infon><infon key="type">Disease</infon><location offset="4611" length="19" /><text>primary lymphoedema</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4998</offset><text>In 2020, heterozygous missense mutations in angiopoietin-2 (ANGPT2) were reported to cause primary lymphoedema with reduced penetrance and variable expressivity in five unrelated families, implicating another endothelial growth factor receptor pathway, the ANGPT2-TIE2 tyrosine kinase pathway. In these families, lymphoedema was not severe and tended to resolve during childhood.</text><annotation id="20302"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="5042" length="14" /><text>angiopoietin-2</text></annotation><annotation id="20303"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="5058" length="6" /><text>ANGPT2</text></annotation><annotation id="20304"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="5255" length="6" /><text>ANGPT2</text></annotation><annotation id="20305"><infon key="identifier">7010</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="5262" length="4" /><text>TIE2</text></annotation><annotation id="20306"><infon key="identifier">7294</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2497</infon><location offset="5267" length="15" /><text>tyrosine kinase</text></annotation><annotation id="20307"><infon key="identifier">MESH:D010538</infon><infon key="type">Disease</infon><location offset="5089" length="19" /><text>primary lymphoedema</text></annotation><annotation id="20308"><infon key="type">Disease</infon><location offset="5311" length="11" /><text>lymphoedema</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5380</offset><text>ANGPT2 disrupts angiogenesis in the developing embryo by antagonising the effects of angiopoietin-1 and Tie2. In mice, homozygous deletion of ANGPT2 or treatment with Angpt2-blocking antibodies results in morphologically and functionally abnormal lymphatics and neonatal death. Pathogenic ANGPT2 variants identified in lymphoedema in humans and studied in mice affect protein function via haploinsufficiency or a dominant-negative mechanism. The resultant reduced ANGPT2 secretion or ANGPT2 binding to integrins causes dysplastic lymphatic vasculature in murine ear skin. </text><annotation id="20309"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="5380" length="6" /><text>ANGPT2</text></annotation><annotation id="20310"><infon key="identifier">284</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37447</infon><location offset="5465" length="14" /><text>angiopoietin-1</text></annotation><annotation id="20311"><infon key="identifier">7010</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="5484" length="4" /><text>Tie2</text></annotation><annotation id="20312"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="5522" length="6" /><text>ANGPT2</text></annotation><annotation id="20313"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="5547" length="6" /><text>Angpt2</text></annotation><annotation id="20314"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="5669" length="6" /><text>ANGPT2</text></annotation><annotation id="20315"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="5844" length="6" /><text>ANGPT2</text></annotation><annotation id="20316"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="5864" length="6" /><text>ANGPT2</text></annotation><annotation id="20317"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="5493" length="4" /><text>mice</text></annotation><annotation id="20318"><infon key="identifier">MESH:D008206</infon><infon key="type">Disease</infon><location offset="5899" length="32" /><text>dysplastic lymphatic vasculature</text></annotation><annotation id="20319"><infon key="identifier">MESH:D066087</infon><infon key="type">Disease</infon><location offset="5642" length="14" /><text>neonatal death</text></annotation><annotation id="20320"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="5935" length="6" /><text>murine</text></annotation><annotation id="20321"><infon key="type">Disease</infon><location offset="5699" length="11" /><text>lymphoedema</text></annotation><annotation id="20322"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="5714" length="6" /><text>humans</text></annotation><annotation id="20323"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="5736" length="4" /><text>mice</text></annotation></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5953</offset><text>Here we report a consanguineous couple with at least four fetuses with severe early-onset NIHF and homozygosity for a loss-of-function (LOF) variant in ANGPT2. This work underscores the pivotal role of ANGPT2 in lymphatic development and adds to the growing list of genes associated with NIHF.</text><annotation id="20324"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="6105" length="6" /><text>ANGPT2</text></annotation><annotation id="20325"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="6155" length="6" /><text>ANGPT2</text></annotation><annotation id="20326"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="6043" length="4" /><text>NIHF</text></annotation><annotation id="20327"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="6241" length="4" /><text>NIHF</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>6247</offset><text>Patients and methods</text><annotation id="20328"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="6247" length="8" /><text>Patients</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6268</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>6276</offset><text>Nucleic acid extraction</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6300</offset><text>DNA was extracted from EDTA blood with EZ1 DSP DNA Blood Kit using an EZ1 Advanced XL (QIAGEN) from amniocytes (for WES) and chorion villus biopsies (for SNP array analysis) using QiaSymphony (QIAGEN) or QIAamp DNA Micro Kit (QIAGEN). For quantitative fluorescent (QF)-PCR analysis of amniocytes and chorion villus biopsies, rapid DNA extraction was performed using InstaGene Matrix Chelex 100 (Bio-Rad, California, USA).</text><annotation id="20329"><infon key="identifier">-</infon><infon key="type">Chemical</infon><location offset="6666" length="9" /><text>InstaGene</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6722</offset><text>RNA was extracted from whole blood using TRIzol reagent (Invitrogen, California, USA) and retrotranscribed with moloney murine leukaemia virus RT (ThermoFisher, Massachusetts, USA). For RT-PCR, primers were chosen in exons distant from those carrying the pathogenic variant NM_001147.2: c.557A&gt;G and the benign marker variant NM_001147.2:c.882G&gt;A (sequences available on request). RNA was also isolated from cultured fibroblasts derived from a paternal skin biopsy.</text><annotation id="20330"><infon key="identifier">tmVar:c|SUB|G|882|A;HGVS:c.882G&gt;A;VariantGroup:4;OriginalGene:11601;CorrespondingGene:285;RS#:1961222;CorrespondingSpecies:10090;CA#:172506</infon><infon key="type">DNAMutation</infon><location offset="7060" length="8" /><text>c.882G&gt;A</text></annotation><annotation id="20331"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="7009" length="8" /><text>c.557A&gt;G</text></annotation><annotation id="20332"><infon key="type">Species</infon><location offset="6834" length="30" /><text>moloney murine leukaemia virus</text></annotation><annotation id="20333"><infon key="identifier">MESH:C411644</infon><infon key="type">Chemical</infon><location offset="6763" length="6" /><text>TRIzol</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>7190</offset><text>ELISA measurements of ANGPT2</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7219</offset><text>ANGPT2 protein levels were measured in blood-EDTA plasma using the Human Angiopoietin-2 Quantikine ELISA Kit (R&amp;D Systems, Minnesota, USA), according to the manufacturer's protocol.</text><annotation id="20334"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="7219" length="6" /><text>ANGPT2</text></annotation><annotation id="20335"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="7292" length="14" /><text>Angiopoietin-2</text></annotation><annotation id="20336"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="7286" length="5" /><text>Human</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>7403</offset><text>Whole exome sequencing</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7426</offset><text>Nextera Rapid Capture Exome sample prep and enrichment (Illumina, California, USA) were carried out according to the manufacturer's instructions. Libraries were sequenced 2x150 bp on a NextSeq500 (Illumina). Bcl2fastq2 conversion software (Illumina) was used for de-multiplexing. Reads were aligned to reference genome GRCh37/hg19 using Burrows-Wheeler Aligner, BWA. Picard was used to remove PCR duplicates. The Genome Analysis Toolkit was applied for base quality score recalibration, insertion and deletion (INDEL) realignment, and single nucleotide variant and INDEL discovery. Sequence variants were annotated with Annovar. Regions of homozygosity were detected using BCFtools/Samtools. Filtus software was used for bioinformatic filtering of variants. Integrative Genomics Viewer was used for NGS data visualisation. Splice site predictions were performed using SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer and Human Splicing Finder through Alamut Visual software (Interactive Biosoftware, Rouen, France).</text><annotation id="20337"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="8350" length="5" /><text>Human</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8450</offset><text>Samples from both parents, four affected fetuses and one clinically unaffected child were exome-sequenced. ANGPT2 was analysed by NGS in a blood sample from the maternal aunt (II-6) as a control of her Sanger sequencing result.</text><annotation id="20338"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="8557" length="6" /><text>ANGPT2</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>8678</offset><text>Sanger sequencing</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8696</offset><text>DNA from samples II-6 (including a control sample) and III-9 were Sanger-sequenced on an ABI 3130xl using standard protocols to determine ANGPT2 genotype. For the other samples, Sanger sequencing was used to verify ANGPT2 results from NGS.</text><annotation id="20339"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="8834" length="6" /><text>ANGPT2</text></annotation><annotation id="20340"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="8911" length="6" /><text>ANGPT2</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>8936</offset><text>QF-PCR (III-4, III-5 and III-7)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8970</offset><text>QF-PCR/rapid aneuploidy diagnostics test was performed with the Elucigene QST*Rplusv2 Kit (Elucigene Diagnostics, Manchester, England). Fragments were analysed using capillary electrophoresis on ABI 3500xl Genetic Analyzer (Applied Biosystems, California, USA) with accompanying GeneMapper software according to the manufacturer's protocols.</text><annotation id="20341"><infon key="identifier">MESH:D000782</infon><infon key="type">Disease</infon><location offset="8983" length="10" /><text>aneuploidy</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>9314</offset><text>Standard G-banding/karyotyping of amniocytes and parental blood samples (III-4, II-1 and II-2)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9409</offset><text>G-banding of metaphase chromosomes was performed on amniocytes from fetus III-4 and sodium-heparin peripheral blood samples from the parents (II-1 and II-2) according to standard protocols.</text><annotation id="20342"><infon key="identifier">MESH:D006493</infon><infon key="type">Chemical</infon><location offset="9493" length="14" /><text>sodium-heparin</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>9599</offset><text>SNP array analysis (III-4, III-5 and III-7)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9643</offset><text>Molecular karyotyping of DNA extracted from amniocytes and chorion villi was performed using SNP array analysis (CytoScan HD; Affymetrix, California, USA). Filtering of data from SNP array analysis was performed using ChAS (Chromosome Analysis Suite) software (Affymetrix) and Cartagenia Bench Lab CNV (Agilent Technologies, California, USA). Positions refer to Genome Reference Consortium Human Genome Build 37 (GRCh37) (hg19). The following were the filter settings for analysis: 400 kb and 30 markers for loss, 90 markers for gains; 5 Mb and 50 SNP markers for regions of homozygosity.</text><annotation id="20343"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="10033" length="5" /><text>Human</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>10236</offset><text>Lymphohistochemical staining in postmortem samples (III-4 and III-5)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10305</offset><text>Lymphohistochemical staining in skin/subcutaneous tissue from the neck and lung was performed on formalin-fixed paraffin-embedded (FFPE) tissue sections with marker D2-40 (podoplanin) (Roche) for lymphatic endothelium.</text><annotation id="20344"><infon key="identifier">10630</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">4729</infon><location offset="10477" length="10" /><text>podoplanin</text></annotation><annotation id="20345"><infon key="identifier">MESH:D005557</infon><infon key="type">Chemical</infon><location offset="10402" length="8" /><text>formalin</text></annotation><annotation id="20346"><infon key="identifier">MESH:D010232</infon><infon key="type">Chemical</infon><location offset="10417" length="8" /><text>paraffin</text></annotation></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_3</infon><offset>10524</offset><text>Placental examination (III-4 and III-5)</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10564</offset><text>Placental FFPE tissue was stained with H&amp;E according to the manufacturer's protocol to visualise the microanatomy of the placenta (nuclear components, cytoplasmic collagen and elastic fibres, muscle fibres and red blood cells).</text><annotation id="20347"><infon key="identifier">MESH:D006371</infon><infon key="type">Chemical</infon><location offset="10603" length="3" /><text>H&amp;E</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>10794</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>10802</offset><text>Clinical summary</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10819</offset><text>The clinical and molecular findings are summarised in table 1 and figure 1.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="type">table_caption</infon><offset>10895</offset><text>Clinical information of the members of a family with ANGPT2 c.557A&gt;G r.557_566del</text><annotation id="20348"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="10948" length="6" /><text>ANGPT2</text></annotation><annotation id="20349"><infon key="identifier">tmVar:c|DEL|557,557_566|G;HGVS:c.557,557_566delG;VariantGroup:11;CorrespondingGene:285;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="10955" length="21" /><text>c.557A&gt;G r.557_566del</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T1.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;Individual/pregnancy&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;III-3&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;III-4&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;III-5&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;III-7&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;III-8&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;III-9&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;II-1&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;II-2&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;II-6&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Phenotype&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Healthy girl&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;IUFD, week 24+2&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;IUFD, week 27+3&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;TOP, week 14&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Miscarriage, week 14&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Healthy boy&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Healthy father&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Healthy mother&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Maternal aunt&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Sex&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Male&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Male&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Male&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Male&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Male&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Sample/analysis&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Blood&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Amnion&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;CVS&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Amnion&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Fibroblasts&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Umbilical cord&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Blood&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Blood&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Blood&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Analysis&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;WES&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;WES&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;WES&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;WES&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;WES&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Sanger&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;WES&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;WES&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Sanger, WES&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Genotype&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Het&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Hom&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Hom&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Hom&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Hom&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Het&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Het&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Het&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;WT/WT&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Outcome&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Healthy.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Severe, progressive hydrops, IUFD week 24.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Severe, progressive hydrops, IUFD week 27.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Early detected severe hydrops, TOP week 14.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Early detected severe hydrops, spontaneous abortion week 14.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Healthy.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Healthy.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Healthy.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;'Oedema' in childhood, lower extremity lymphoedema.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Early US, including NT&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 11+2 normal, no measurement of NT.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 11 normal, no measurement of NT.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 12+3 NT 5.0, cystic hygroma subcutaneous fluid.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 12+4 cystic hygroma, subcutaneous fluid.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 11+0 NT 3.7,&lt;break/&gt;generalised subcutaneous fluid, cystic hygroma.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 12+4 NT 4.5&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Later US&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 18 normal.&lt;break/&gt;Week 32 normal.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 19+5 (LMP).&lt;break/&gt;Week 17 (US) screening hydrothorax, ascites, subcutaneous fluid.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 16 hydrothorax, subcutaneous fluid, cystic hygroma.&lt;break/&gt;Week 26 ascites.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 14+4 cystic hygroma and hydrothorax.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 12+1 NT 6-7 mm.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Week 14+2 NT normal.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;PM&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Yes&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Yes&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Cardiac&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Tetralogy of Fallot&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Normal at PM&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Skeletal/growth&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;2-week discrepancy EDD from LMP and from US.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Short long bones, bell-shaped thorax (due to hydrothorax/hypoplastic lungs.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;IHC in lymphatic endothelium&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;No observed increase in number of lymphatic vessels&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;No observed increase in number of lymphatic vessels&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Placenta&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Hydropic placenta.&lt;break/&gt;Thick (3 cm), oedematous.&lt;break/&gt;Weight 360 g.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Hydropic placenta.&lt;break/&gt;Thick (2,9 cm).&lt;break/&gt;Weight 440 g.&lt;break/&gt;Abnormal vascular architecture/proliferation of vessels.&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NA&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">T1</infon><infon key="type">table</infon><offset>10979</offset><text>Individual/pregnancy III-3 III-4 III-5 III-7 III-8 III-9 II-1 II-2 II-6   Phenotype Healthy girl IUFD, week 24+2 IUFD, week 27+3 TOP, week 14 Miscarriage, week 14 Healthy boy Healthy father Healthy mother Maternal aunt   Sex Female Male Female Male Male Male Male Female Female   Sample/analysis Blood Amnion CVS Amnion Fibroblasts Umbilical cord Blood Blood Blood   Analysis WES WES WES WES WES Sanger WES WES Sanger, WES   Genotype Het Hom Hom Hom Hom Het Het Het WT/WT   Outcome Healthy. Severe, progressive hydrops, IUFD week 24. Severe, progressive hydrops, IUFD week 27. Early detected severe hydrops, TOP week 14. Early detected severe hydrops, spontaneous abortion week 14. Healthy. Healthy. Healthy. 'Oedema' in childhood, lower extremity lymphoedema.   Early US, including NT Week 11+2 normal, no measurement of NT. Week 11 normal, no measurement of NT. Week 12+3 NT 5.0, cystic hygroma subcutaneous fluid. Week 12+4 cystic hygroma, subcutaneous fluid. Week 11+0 NT 3.7,generalised subcutaneous fluid, cystic hygroma. Week 12+4 NT 4.5 - - -   Later US Week 18 normal.Week 32 normal. Week 19+5 (LMP).Week 17 (US) screening hydrothorax, ascites, subcutaneous fluid. Week 16 hydrothorax, subcutaneous fluid, cystic hygroma.Week 26 ascites. Week 14+4 cystic hygroma and hydrothorax. Week 12+1 NT 6-7 mm. Week 14+2 NT normal. - - -   PM NA Yes Yes NA NA NA - - -   Cardiac NA Tetralogy of Fallot Normal at PM NA NA NA - - -   Skeletal/growth NA 2-week discrepancy EDD from LMP and from US. Short long bones, bell-shaped thorax (due to hydrothorax/hypoplastic lungs. NA NA NA - - -   IHC in lymphatic endothelium NA No observed increase in number of lymphatic vessels No observed increase in number of lymphatic vessels NA NA NA - - -   Placenta NA Hydropic placenta.Thick (3 cm), oedematous.Weight 360 g. Hydropic placenta.Thick (2,9 cm).Weight 440 g.Abnormal vascular architecture/proliferation of vessels. NA NA NA - - -   </text><annotation id="20350"><infon key="identifier">MESH:D008171</infon><infon key="type">Disease</infon><location offset="12531" length="17" /><text>hypoplastic lungs</text></annotation><annotation id="20351"><infon key="type">Disease</infon><location offset="11801" length="2" /><text>NT</text></annotation><annotation id="20352"><infon key="type">Disease</infon><location offset="12278" length="2" /><text>NT</text></annotation><annotation id="20353"><infon key="identifier">MESH:D018191</infon><infon key="type">Disease</infon><location offset="11913" length="7" /><text>hygroma</text></annotation><annotation id="20354"><infon key="identifier">MESH:D018191</infon><infon key="type">Disease</infon><location offset="11868" length="7" /><text>hygroma</text></annotation><annotation id="20355"><infon key="type">Disease</infon><location offset="11076" length="4" /><text>IUFD</text></annotation><annotation id="20356"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="11622" length="7" /><text>hydrops</text></annotation><annotation id="20357"><infon key="identifier">MESH:D018297</infon><infon key="type">Disease</infon><location offset="12194" length="6" /><text>cystic</text></annotation><annotation id="20358"><infon key="type">Disease</infon><location offset="12299" length="2" /><text>NT</text></annotation><annotation id="20359"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="11533" length="7" /><text>hydrops</text></annotation><annotation id="20360"><infon key="type">Disease</infon><location offset="11762" length="2" /><text>NT</text></annotation><annotation id="20361"><infon key="type">Disease</infon><location offset="12764" length="10" /><text>oedematous</text></annotation><annotation id="20362"><infon key="identifier">MESH:D018191</infon><infon key="type">Disease</infon><location offset="11998" length="7" /><text>hygroma</text></annotation><annotation id="20363"><infon key="identifier">MESH:D006876</infon><infon key="type">Disease</infon><location offset="12161" length="11" /><text>hydrothorax</text></annotation><annotation id="20364"><infon key="identifier">MESH:D001201</infon><infon key="type">Disease</infon><location offset="12217" length="7" /><text>ascites</text></annotation><annotation id="20365"><infon key="identifier">MESH:D018297</infon><infon key="type">Disease</infon><location offset="11991" length="6" /><text>cystic</text></annotation><annotation id="20366"><infon key="type">Disease</infon><location offset="12017" length="2" /><text>NT</text></annotation><annotation id="20367"><infon key="identifier">MESH:C536897</infon><infon key="type">Disease</infon><location offset="11689" length="6" /><text>Oedema</text></annotation><annotation id="20368"><infon key="identifier">MESH:D000026</infon><infon key="type">Disease</infon><location offset="11643" length="8" /><text>abortion</text></annotation><annotation id="20369"><infon key="identifier">MESH:D013771</infon><infon key="type">Disease</infon><location offset="12360" length="19" /><text>Tetralogy of Fallot</text></annotation><annotation id="20370"><infon key="type">Disease</infon><location offset="11499" length="4" /><text>IUFD</text></annotation><annotation id="20371"><infon key="type">Disease</infon><location offset="11853" length="2" /><text>NT</text></annotation><annotation id="20372"><infon key="type">Disease</infon><location offset="12448" length="3" /><text>EDD</text></annotation><annotation id="20373"><infon key="type">Disease</infon><location offset="11542" length="4" /><text>IUFD</text></annotation><annotation id="20374"><infon key="identifier">MESH:D010291</infon><infon key="type">Disease</infon><location offset="11711" length="27" /><text>lower extremity lymphoedema</text></annotation><annotation id="20375"><infon key="identifier">MESH:D018297</infon><infon key="type">Disease</infon><location offset="11906" length="6" /><text>cystic</text></annotation><annotation id="20376"><infon key="identifier">MESH:D006876</infon><infon key="type">Disease</infon><location offset="12255" length="11" /><text>hydrothorax</text></annotation><annotation id="20377"><infon key="type">Disease</infon><location offset="11092" length="4" /><text>IUFD</text></annotation><annotation id="20378"><infon key="identifier">MESH:D001201</infon><infon key="type">Disease</infon><location offset="12124" length="7" /><text>ascites</text></annotation><annotation id="20379"><infon key="identifier">MESH:D018297</infon><infon key="type">Disease</infon><location offset="11861" length="6" /><text>cystic</text></annotation><annotation id="20380"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="11490" length="7" /><text>hydrops</text></annotation><annotation id="20381"><infon key="type">Disease</infon><location offset="11952" length="2" /><text>NT</text></annotation><annotation id="20382"><infon key="identifier">MESH:D006876</infon><infon key="type">Disease</infon><location offset="12111" length="11" /><text>hydrothorax</text></annotation><annotation id="20383"><infon key="identifier">MESH:D018191</infon><infon key="type">Disease</infon><location offset="12201" length="7" /><text>hygroma</text></annotation><annotation id="20384"><infon key="identifier">MESH:D018191</infon><infon key="type">Disease</infon><location offset="12243" length="7" /><text>hygroma</text></annotation><annotation id="20385"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="11578" length="7" /><text>hydrops</text></annotation><annotation id="20386"><infon key="identifier">MESH:D018297</infon><infon key="type">Disease</infon><location offset="12236" length="6" /><text>cystic</text></annotation><annotation id="20387"><infon key="identifier">MESH:D006876</infon><infon key="type">Disease</infon><location offset="12519" length="11" /><text>hydrothorax</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="type">table_footnote</infon><offset>12968</offset><text>Created by the authors.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="type">table_footnote</infon><offset>12992</offset><text>CVS, chorionic villous biopsy; EDD, estimated due date; Het, heterozygous; Hom, homozygous; IHC, immunohistochemistry; IUFD, intrauterine fetal death; LMP, last menstrual period; NA, not assessed/not applicable; NT, nuchal translucency; PM, postmortem examination; TOP, termination of pregnancy; US, ultrasound; WES, whole exome sequencing; WT, wild-type.</text><annotation id="20388"><infon key="type">Disease</infon><location offset="13023" length="3" /><text>EDD</text></annotation><annotation id="20389"><infon key="type">Disease</infon><location offset="13204" length="2" /><text>NT</text></annotation><annotation id="20390"><infon key="type">Disease</infon><location offset="13111" length="4" /><text>IUFD</text></annotation><annotation id="20391"><infon key="identifier">MESH:D005313</infon><infon key="type">Disease</infon><location offset="13117" length="24" /><text>intrauterine fetal death</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">jmedgenet-2021-108179f01.jpg</infon><infon key="id">F1</infon><infon key="type">fig_caption</infon><offset>13348</offset><text>Pedigree of a family with ANGPT2 c.557A&gt;G r.557_566del. Triangles in black are fetal losses with hydrops fetalis, and white triangles with question mark are early pregnancy losses not amenable to evaluation. Created by the authors. Het, heterozygous NM_001147.2:c.557A&gt;G r.557_566del; Hom, homozygous NM_001147.2:c.557A&gt;G r.557_566del; N/A, not available for genetic analysis; WT, wild-type, homozygous NM_001147.2:c.557A r.557A.</text><annotation id="20392"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="13374" length="6" /><text>ANGPT2</text></annotation><annotation id="20393"><infon key="identifier">tmVar:p|SUB|N||A;VariantGroup:21;CorrespondingGene:285;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="13684" length="3" /><text>N/A</text></annotation><annotation id="20394"><infon key="identifier">tmVar:c|DEL|557,557_566|G;HGVS:c.557,557_566delG;VariantGroup:11;CorrespondingGene:285;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="13381" length="21" /><text>c.557A&gt;G r.557_566del</text></annotation><annotation id="20395"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="13445" length="15" /><text>hydrops fetalis</text></annotation><annotation id="20396"><infon key="identifier">MESH:D005315</infon><infon key="type">Disease</infon><location offset="13427" length="12" /><text>fetal losses</text></annotation><annotation id="20397"><infon key="identifier">tmVar:c|DEL|557,557_566|G;HGVS:c.557,557_566delG;VariantGroup:11;CorrespondingGene:285;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="13661" length="21" /><text>c.557A&gt;G r.557_566del</text></annotation><annotation id="20398"><infon key="identifier">MESH:D000022</infon><infon key="type">Disease</infon><location offset="13511" length="16" /><text>pregnancy losses</text></annotation><annotation id="20399"><infon key="identifier">tmVar:c|DEL|557,557_566|G;HGVS:c.557,557_566delG;VariantGroup:11;CorrespondingGene:285;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="13610" length="21" /><text>c.557A&gt;G r.557_566del</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>13784</offset><text>The healthy mother (II-1) and father (II-2) are second cousins once removed and originally from central Asia. She has polycystic ovary syndrome. Both parents have normal haemoglobin profiles and neither harbours an alpha-globin deletion. Maternal parvovirus serum IgG in the fifth pregnancy was indicative of previous infection. Screening for maternal erythrocyte and platelet antibodies was negative. Standard karyotyping (G-band analysis) of the parents was normal. There is no clinical suspicion of lymphoedema in either parent, although their prenatal and neonatal histories are not available.</text><annotation id="20400"><infon key="identifier">3040</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">469</infon><location offset="13999" length="12" /><text>alpha-globin</text></annotation><annotation id="20401"><infon key="identifier">MESH:D007239</infon><infon key="type">Disease</infon><location offset="14102" length="9" /><text>infection</text></annotation><annotation id="20402"><infon key="type">Species</infon><location offset="14022" length="19" /><text>Maternal parvovirus</text></annotation><annotation id="20403"><infon key="type">Disease</infon><location offset="14286" length="11" /><text>lymphoedema</text></annotation><annotation id="20404"><infon key="identifier">MESH:D011085</infon><infon key="type">Disease</infon><location offset="13902" length="25" /><text>polycystic ovary syndrome</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>14382</offset><text>The mother presented at age 26 years in the second trimester of her fourth pregnancy (III-4) due to fetal hydrops. Fetal ultrasound at 11+5 weeks had been reported as normal, although nuchal translucency was not assessed. Routine ultrasound at 19+5 weeks revealed a male fetus (III-4) with severe hydrops. Additional findings included gestational age by ultrasound at 17+4 weeks, no evidence of fetal anaemia based on cerebral artery Doppler, and negative rapid testing for trisomy 13, 18 and 21 and cytogenetic karyotyping in amniocytes. Maternal serology and PCR analysis of amniotic fluid detected no evidence of a viral infection. At 20 weeks, fluid accumulation was increased and tetralogy of Fallot was noted. Intrauterine death occurred at 26+3 weeks.</text><annotation id="20405"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="14679" length="7" /><text>hydrops</text></annotation><annotation id="20406"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="15098" length="18" /><text>Intrauterine death</text></annotation><annotation id="20407"><infon key="identifier">MESH:D005315</infon><infon key="type">Disease</infon><location offset="14777" length="13" /><text>fetal anaemia</text></annotation><annotation id="20408"><infon key="identifier">MESH:D000073839</infon><infon key="type">Disease</infon><location offset="14856" length="21" /><text>trisomy 13, 18 and 21</text></annotation><annotation id="20409"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="14482" length="13" /><text>fetal hydrops</text></annotation><annotation id="20410"><infon key="identifier">MESH:D014777</infon><infon key="type">Disease</infon><location offset="15000" length="15" /><text>viral infection</text></annotation><annotation id="20411"><infon key="identifier">MESH:D013771</infon><infon key="type">Disease</infon><location offset="15067" length="19" /><text>tetralogy of Fallot</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15141</offset><text>The mother's first pregnancy ended in an early miscarriage (III-1).</text><annotation id="20412"><infon key="identifier">MESH:D000022</infon><infon key="type">Disease</infon><location offset="15188" length="11" /><text>miscarriage</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15211</offset><text>The couple has a healthy daughter (III-2) born following a normal pregnancy in which an ultrasound at 11+2 weeks was reported as normal, although nuchal translucency was not assessed. She is now school-aged and there is no suspicion of oedema anamnestically.</text><annotation id="20413"><infon key="identifier">MESH:C536897</infon><infon key="type">Disease</infon><location offset="15447" length="6" /><text>oedema</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15470</offset><text>The third pregnancy resulted in a miscarriage (III-3) at 9 weeks.</text><annotation id="20414"><infon key="identifier">MESH:D000022</infon><infon key="type">Disease</infon><location offset="15504" length="11" /><text>miscarriage</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>15536</offset><text>In the fifth pregnancy, severe hydrops including a large nuchal cyst was detected at 12 weeks in the female fetus (III-5). Results of rapid testing for trisomy 13, 18 and 21 and chromosomal microarray on DNA extracted from a chorionic villus biopsy were normal. The hydrops progressed and the couple was informed of a poor prognosis, including the risk of maternal mirror syndrome. Fetal demise occurred at 27 weeks (figure 2). Autopsy revealed severe hydrops with hydrothorax, hypoplastic lungs, a bell-shaped thorax, short long bones and a hydropic placenta.</text><annotation id="20415"><infon key="identifier">MESH:D006876</infon><infon key="type">Disease</infon><location offset="16001" length="11" /><text>hydrothorax</text></annotation><annotation id="20416"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="15567" length="7" /><text>hydrops</text></annotation><annotation id="20417"><infon key="identifier">MESH:D005313</infon><infon key="type">Disease</infon><location offset="15918" length="12" /><text>Fetal demise</text></annotation><annotation id="20418"><infon key="identifier">MESH:D000073839</infon><infon key="type">Disease</infon><location offset="15688" length="21" /><text>trisomy 13, 18 and 21</text></annotation><annotation id="20419"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="15988" length="7" /><text>hydrops</text></annotation><annotation id="20420"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="15802" length="7" /><text>hydrops</text></annotation><annotation id="20421"><infon key="identifier">OMIM:157600</infon><infon key="type">Disease</infon><location offset="15892" length="24" /><text>maternal mirror syndrome</text></annotation><annotation id="20422"><infon key="identifier">MESH:D010922</infon><infon key="type">Disease</infon><location offset="16078" length="17" /><text>hydropic placenta</text></annotation><annotation id="20423"><infon key="identifier">MESH:D008171</infon><infon key="type">Disease</infon><location offset="16014" length="17" /><text>hypoplastic lungs</text></annotation><annotation id="20424"><infon key="identifier">MESH:D003560</infon><infon key="type">Disease</infon><location offset="15593" length="11" /><text>nuchal cyst</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">jmedgenet-2021-108179f02.jpg</infon><infon key="id">F2</infon><infon key="type">fig_caption</infon><offset>16097</offset><text>Photograph of a fetus (III-5) with intrauterine death at 27 gestational weeks. Note the severe subcutaneous oedemas, deformed facial features and large cystic hygroma of the neck. Created by the authors.</text><annotation id="20425"><infon key="identifier">MESH:D013352</infon><infon key="type">Disease</infon><location offset="16192" length="20" /><text>subcutaneous oedemas</text></annotation><annotation id="20426"><infon key="identifier">MESH:D018191</infon><infon key="type">Disease</infon><location offset="16256" length="7" /><text>hygroma</text></annotation><annotation id="20427"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="16132" length="18" /><text>intrauterine death</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16301</offset><text>The sixth pregnancy ended in a termination (III-6) after detection of a blighted ovum at 10+4 weeks.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16402</offset><text>The seventh pregnancy was terminated (III-7) at 15 weeks after detection of severe subcutaneous oedema and a cystic hygroma at 12+4 weeks. Rapid aneuploidy testing was normal. Chromosomal microarray was normal and demonstrated homozygosity stretches in common with fetuses III-4 and III-5, in keeping with parental consanguinity.</text><annotation id="20428"><infon key="identifier">MESH:D018191</infon><infon key="type">Disease</infon><location offset="16511" length="14" /><text>cystic hygroma</text></annotation><annotation id="20429"><infon key="identifier">MESH:D000782</infon><infon key="type">Disease</infon><location offset="16547" length="10" /><text>aneuploidy</text></annotation><annotation id="20430"><infon key="identifier">MESH:D013352</infon><infon key="type">Disease</infon><location offset="16485" length="19" /><text>subcutaneous oedema</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16732</offset><text>The eighth pregnancy ended in a miscarriage (III-8) at 14-15 weeks following detection of increased nuchal translucency (week 11+0, 3.7 mm, &gt;99th centile) and severe generalised subcutaneous fluid accumulation.</text><annotation id="20431"><infon key="identifier">MESH:D000022</infon><infon key="type">Disease</infon><location offset="16764" length="11" /><text>miscarriage</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>16947</offset><text>In the ninth pregnancy (III-9), ultrasound at 12+2 gestational weeks showed increased nuchal translucency (4.5 mm, &gt;99th centile) with a narrow brim of subcutaneous fluid extending to the upper back. However, at 14+2 weeks no abnormal fluid accumulation was seen. Pregnancy proceeded uneventfully and a healthy male infant was born at term. He is now 12 months old and there has been no suspicion of oedema at any time.</text><annotation id="20432"><infon key="identifier">MESH:C536897</infon><infon key="type">Disease</infon><location offset="17347" length="6" /><text>oedema</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>17371</offset><text>Clinical assessment of additional family members</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17420</offset><text>Both parents have several siblings, but only the maternal 30-year-old sister (II-6) has been available for investigation. She reported childhood 'oedemas', but her paediatric record is unavailable. In young adulthood, she presented with intermittent swelling of the ankles and feet, especially on the left. Lymphoscintigraphy of her lower extremities failed to visualise the lymphatic vessels or the inguinal nodes on the left. In the right leg, delayed clearance and several foci of increased uptake were interpreted as evidence of abnormal lymphatic vessels morphology.</text><annotation id="20433"><infon key="identifier">MESH:D016512</infon><infon key="type">Disease</infon><location offset="17670" length="22" /><text>swelling of the ankles</text></annotation><annotation id="20434"><infon key="identifier">MESH:C536897</infon><infon key="type">Disease</infon><location offset="17566" length="7" /><text>oedemas</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>17996</offset><text>Whole exome sequencing</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18019</offset><text>WES revealed rare, coding or splice site variants compatible with autosomal recessive inheritance in seven genes not previously been associated with hydrops fetalis (table 2). These were submitted to GeneMatcher. The only potentially relevant match was for ANGPT2, a case series with autosomal dominant lymphoedema, which was then unpublished. Subsequently, in a new pregnancy with an affected fetus (III-8), exome sequencing excluded all candidate genes except ANGPT2. The detected variant in our family, (GRCh37/Hg19): 8:6385085T&gt;C, NM_001147.2:c.557A&gt;G p.(Asp186Gly) in exon 3, was identified in the homozygous state in all investigated hydropic fetuses and in the heterozygous state in the unaffected parents (figure 1 and table 1). The ANGPT2 variant was absent from gnomAD and predicted activation of a cryptic 5' splice site between c.556 and c.557, leading to removal of 10 bp from the 3' end of exon 3 and introduction of a premature termination codon: r.557_566del p.(Asp186Valdelfs*3).</text><annotation id="20435"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="18276" length="6" /><text>ANGPT2</text></annotation><annotation id="20436"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="18481" length="6" /><text>ANGPT2</text></annotation><annotation id="20437"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="18760" length="6" /><text>ANGPT2</text></annotation><annotation id="20438"><infon key="identifier">tmVar:g|SUB|T|6385085|C;HGVS:g.6385085T&gt;C;VariantGroup:22;CorrespondingGene:285;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="18542" length="10" /><text>6385085T&gt;C</text></annotation><annotation id="20439"><infon key="identifier">tmVar:p|SUB|D|186|G;HGVS:p.D186G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="18575" length="13" /><text>p.(Asp186Gly)</text></annotation><annotation id="20440"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="18168" length="15" /><text>hydrops fetalis</text></annotation><annotation id="20441"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="18566" length="8" /><text>c.557A&gt;G</text></annotation><annotation id="20442"><infon key="identifier">MESH:C566739</infon><infon key="type">Disease</infon><location offset="18303" length="30" /><text>autosomal dominant lymphoedema</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="type">table_caption</infon><offset>19024</offset><text>Candidate genes</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T2.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;Gene&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;Chromosome&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;Position&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;Reference allele&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;Alternative allele&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;cDNA change&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;Protein change&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;gnomAD popmax&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt; &lt;italic toggle="yes"&gt;ANGPT2&lt;/italic&gt; &lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;8&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;6385085&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;T&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;C&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NM_001147.2:c.557A&amp;gt;G&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;p.(Asp186Gly)&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt; &lt;italic toggle="yes"&gt;CYP2C19&lt;/italic&gt; &lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;10&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;96535218&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;G&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;C&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NM_000769.2:c.403G&amp;gt;C&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;p.(Gly135Arg)&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt; &lt;italic toggle="yes"&gt;RRP12&lt;/italic&gt; &lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;10&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;99118361&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;C&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;T&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NM_015179.1:c.3724G&amp;gt;A&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;p.(Val1242Met)&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;20/30616 South Asian alleles&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt; &lt;italic toggle="yes"&gt;LOXL4&lt;/italic&gt; &lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;10&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;100016620&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;C&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;T&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NM_032211.6:c.1345G&amp;gt;A&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;p.(Val449Met)&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;14/30616 South Asian alleles&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt; &lt;italic toggle="yes"&gt;PYROXD2&lt;/italic&gt; &lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;10&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;100154981&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;T&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;C&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NM_032709.2:c.757A&amp;gt;G&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;p.(Met253Val)&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;18/30616 South Asian alleles&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt; &lt;italic toggle="yes"&gt;SH3PXD2A&lt;/italic&gt; &lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;10&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;105362591&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;G&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;A&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NM_014631.1:c.2300C&amp;gt;T&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;p.(Ser767Phe)&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;9/30612 South Asian alleles&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt; &lt;italic toggle="yes"&gt;TECTB&lt;/italic&gt; &lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;10&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;114044422&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;A&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;T&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;NM_058222.2:c.206A&amp;gt;T&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;p.(Tyr69Phe)&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;5/30356 South Asian alleles (1 homozygote)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">T2</infon><infon key="type">table</infon><offset>19040</offset><text>Gene Chromosome Position Reference allele Alternative allele cDNA change Protein change gnomAD popmax   ANGPT2 8 6385085 T C NM_001147.2:c.557A&gt;G p.(Asp186Gly) 0   CYP2C19 10 96535218 G C NM_000769.2:c.403G&gt;C p.(Gly135Arg) 0   RRP12 10 99118361 C T NM_015179.1:c.3724G&gt;A p.(Val1242Met) 20/30616 South Asian alleles   LOXL4 10 100016620 C T NM_032211.6:c.1345G&gt;A p.(Val449Met) 14/30616 South Asian alleles   PYROXD2 10 100154981 T C NM_032709.2:c.757A&gt;G p.(Met253Val) 18/30616 South Asian alleles   SH3PXD2A 10 105362591 G A NM_014631.1:c.2300C&gt;T p.(Ser767Phe) 9/30612 South Asian alleles   TECTB 10 114044422 A T NM_058222.2:c.206A&gt;T p.(Tyr69Phe) 5/30356 South Asian alleles (1 homozygote)   </text><annotation id="20443"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="19144" length="6" /><text>ANGPT2</text></annotation><annotation id="20444"><infon key="identifier">1557</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">133565</infon><location offset="19204" length="7" /><text>CYP2C19</text></annotation><annotation id="20445"><infon key="identifier">23223</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22370</infon><location offset="19267" length="5" /><text>RRP12</text></annotation><annotation id="20446"><infon key="identifier">84171</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">12977</infon><location offset="19357" length="5" /><text>LOXL4</text></annotation><annotation id="20447"><infon key="identifier">84795</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">13097</infon><location offset="19447" length="7" /><text>PYROXD2</text></annotation><annotation id="20448"><infon key="identifier">9644</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7317</infon><location offset="19538" length="8" /><text>SH3PXD2A</text></annotation><annotation id="20449"><infon key="identifier">6975</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7568</infon><location offset="19630" length="5" /><text>TECTB</text></annotation><annotation id="20450"><infon key="identifier">tmVar:c|SUB|G|1345|A;HGVS:c.1345G&gt;A;VariantGroup:2;CorrespondingGene:84171;RS#:757386037;CorrespondingSpecies:9606;CA#:5637580</infon><infon key="type">DNAMutation</infon><location offset="19392" length="9" /><text>c.1345G&gt;A</text></annotation><annotation id="20451"><infon key="identifier">tmVar:p|SUB|S|767|F;HGVS:p.S767F;VariantGroup:6;CorrespondingGene:9644;RS#:199845605;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="19586" length="13" /><text>p.(Ser767Phe)</text></annotation><annotation id="20452"><infon key="identifier">tmVar:c|SUB|C|2300|T;HGVS:c.2300C&gt;T;VariantGroup:6;CorrespondingGene:9644;RS#:199845605;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="19576" length="9" /><text>c.2300C&gt;T</text></annotation><annotation id="20453"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="19177" length="8" /><text>c.557A&gt;G</text></annotation><annotation id="20454"><infon key="identifier">tmVar:p|SUB|M|253|V;HGVS:p.M253V;VariantGroup:7;CorrespondingGene:84795;RS#:776182025;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="19493" length="13" /><text>p.(Met253Val)</text></annotation><annotation id="20455"><infon key="identifier">tmVar:p|SUB|Y|69|F;HGVS:p.Y69F;VariantGroup:8;CorrespondingGene:6975;RS#:777846189;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="19674" length="12" /><text>p.(Tyr69Phe)</text></annotation><annotation id="20456"><infon key="identifier">tmVar:c|SUB|A|757|G;HGVS:c.757A&gt;G;VariantGroup:7;CorrespondingGene:84795;RS#:776182025;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="19484" length="8" /><text>c.757A&gt;G</text></annotation><annotation id="20457"><infon key="identifier">tmVar:c|SUB|G|3724|A;HGVS:c.3724G&gt;A;VariantGroup:0;CorrespondingGene:23223;RS#:777545450;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="19301" length="9" /><text>c.3724G&gt;A</text></annotation><annotation id="20458"><infon key="identifier">tmVar:p|SUB|G|135|R;HGVS:p.G135R;VariantGroup:5;OriginalGene:11600;CorrespondingGene:284;RS#:781505587;CorrespondingSpecies:10090</infon><infon key="type">ProteinMutation</infon><location offset="19249" length="13" /><text>p.(Gly135Arg)</text></annotation><annotation id="20459"><infon key="identifier">tmVar:c|SUB|A|206|T;HGVS:c.206A&gt;T;VariantGroup:8;CorrespondingGene:6975;RS#:777846189;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="19665" length="8" /><text>c.206A&gt;T</text></annotation><annotation id="20460"><infon key="identifier">tmVar:c|SUB|G|403|C;HGVS:c.403G&gt;C;VariantGroup:5;OriginalGene:11600;CorrespondingGene:284;RS#:781505587;CorrespondingSpecies:10090</infon><infon key="type">DNAMutation</infon><location offset="19240" length="8" /><text>c.403G&gt;C</text></annotation><annotation id="20461"><infon key="identifier">tmVar:p|SUB|V|1242|M;HGVS:p.V1242M;VariantGroup:0;CorrespondingGene:23223;RS#:777545450;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="19311" length="14" /><text>p.(Val1242Met)</text></annotation><annotation id="20462"><infon key="identifier">tmVar:p|SUB|D|186|G;HGVS:p.D186G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="19186" length="13" /><text>p.(Asp186Gly)</text></annotation><annotation id="20463"><infon key="identifier">tmVar:p|SUB|V|449|M;HGVS:p.V449M;VariantGroup:2;CorrespondingGene:84171;RS#:757386037;CorrespondingSpecies:9606;CA#:5637580</infon><infon key="type">ProteinMutation</infon><location offset="19402" length="13" /><text>p.(Val449Met)</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="type">table_footnote</infon><offset>19733</offset><text>Whole exome sequencing of II-1, II-2, III-2, III-4, III-5 and III-7 revealed rare, coding variants in seven candidate genes which had not previously been associated with hydrops. All variants were entered in GeneMatcher. Sequencing of III-8 had not been undertaken at that time.</text><annotation id="20464"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="19903" length="7" /><text>hydrops</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="type">table_footnote</infon><offset>20012</offset><text>Created by the authors.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>20036</offset><text>Individual II-6 did not carry ANGPT2 c.557A&gt;G. No pathogenic or likely pathogenic variants causative of monogenic lymphoedema were detected in the 40 genes subsequently analysed (PanelApp's 'green' genes, primary lymphoedema; V.2.2, 6 June 2021). </text><annotation id="20465"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="20066" length="6" /><text>ANGPT2</text></annotation><annotation id="20466"><infon key="type">Disease</infon><location offset="20140" length="21" /><text>monogenic lymphoedema</text></annotation><annotation id="20467"><infon key="identifier">MESH:D010538</infon><infon key="type">Disease</infon><location offset="20241" length="19" /><text>primary lymphoedema</text></annotation><annotation id="20468"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="20073" length="8" /><text>c.557A&gt;G</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>20290</offset><text>Sanger sequencing</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>20308</offset><text>The unaffected brother (III-9) was heterozygous for NM_001147.2:c.557A&gt;G, whereas the maternal aunt (II-6) did not carry the variant (a control sample was also analysed by Sanger sequencing and by WES).</text><annotation id="20469"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="20372" length="8" /><text>c.557A&gt;G</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>20511</offset><text>mRNA analyses</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>20525</offset><text>mRNA from the heterozygous parents showed only the wild-type (WT) (A) allele at position c.557 (figure 3). Loss of the allele carrying the likely pathogenic variant c.557A&gt;G was confirmed by genotyping a second variant NM_001147.2:c.882G&gt;A p.(Thr294=) in exon 5, heterozygously present in both parents' DNA. Only the G-allele was observed in mRNA from fibroblasts and lymphocytes. Thus, both parents expressed only a single WT ANGPT2 allele, in keeping with degradation of the mutant allele with a premature termination codon by nonsense-mediated mRNA decay.</text><annotation id="20470"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="20952" length="6" /><text>ANGPT2</text></annotation><annotation id="20471"><infon key="identifier">tmVar:c|SUB|G|882|A;HGVS:c.882G&gt;A;VariantGroup:4;OriginalGene:11601;CorrespondingGene:285;RS#:1961222;CorrespondingSpecies:10090;CA#:172506</infon><infon key="type">DNAMutation</infon><location offset="20756" length="8" /><text>c.882G&gt;A</text></annotation><annotation id="20472"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="20690" length="8" /><text>c.557A&gt;G</text></annotation><annotation id="20473"><infon key="type">Species</infon><location offset="20746" length="9" /><text>_001147.2</text></annotation></passage><passage><infon key="section_type">FIG</infon><infon key="file">jmedgenet-2021-108179f03.jpg</infon><infon key="id">F3</infon><infon key="type">fig_caption</infon><offset>21088</offset><text>DNA and RNA analyses. Sequencing of the pathogenic variant ANGPT2 c.557A&gt;G (heterozygous, represented by an R) and the benign marker variant c.882 G&gt;A (heterozygous C/T in the genomic minus strand alignment from WES) in DNA (top) and RNA isolated from lymphocytes from individual II-1 (bottom). RNA only contains one of the two alleles (WT for the mutation position). Created by the authors. WES, whole exome sequencing; WT, wild-type.</text><annotation id="20474"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="21147" length="6" /><text>ANGPT2</text></annotation><annotation id="20475"><infon key="identifier">tmVar:c|SUB|C||T;VariantGroup:18;CorrespondingGene:285;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="21253" length="3" /><text>C/T</text></annotation><annotation id="20476"><infon key="identifier">tmVar:c|SUB|G|882|A;HGVS:c.882G&gt;A;VariantGroup:4;OriginalGene:11601;CorrespondingGene:285;RS#:1961222;CorrespondingSpecies:10090;CA#:172506</infon><infon key="type">DNAMutation</infon><location offset="21229" length="9" /><text>c.882 G&gt;A</text></annotation><annotation id="20477"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="21154" length="8" /><text>c.557A&gt;G</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21524</offset><text>To confirm that ANGPT2 expression was reduced, plasma concentrations were measured by ELISA. The heterozygous father's plasma concentration was reduced (672.2 pg/mL) (table 3). This is similar to the level measured for the individual with the dominant-negative acting ANGPT2 variant R492Q reported by Leppanen et al. The heterozygous mother was pregnant at the time of sampling. Her serum concentration of ANGPT2 (8294 pg/mL) was increased compared with non-pregnant controls; however, it was approximately half of the mean level (18 900 pg/mL) in pregnant controls (table 3).</text><annotation id="20478"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="21540" length="6" /><text>ANGPT2</text></annotation><annotation id="20479"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="21792" length="6" /><text>ANGPT2</text></annotation><annotation id="20480"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="21930" length="6" /><text>ANGPT2</text></annotation><annotation id="20481"><infon key="identifier">tmVar:p|SUB|R|492|Q;HGVS:p.R492Q;VariantGroup:23;CorrespondingGene:9644;RS#:759640059;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="21807" length="5" /><text>R492Q</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="type">table_caption</infon><offset>22106</offset><text>ELISA of plasma ANGPT2 concentration</text><annotation id="20482"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="22122" length="6" /><text>ANGPT2</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T3.xml</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt; &lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;Individual&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;Gender&lt;/td&gt;&lt;td align="left" valign="bottom" rowspan="1" colspan="1"&gt;Mutation&lt;/td&gt;&lt;td align="left" valign="bottom" colspan="2" rowspan="1"&gt;ANGPT2 plasma concentration (pg/mL)&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Control 1&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;1690&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="9" colspan="1"&gt;2196&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Control 2&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;1197&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Control 3&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Male&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;2354&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Control 4&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;1729&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Control 5&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;1419&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Control 6&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Male&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;2297&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Control 7&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Male&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;1479&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Control 8&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;2844&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Control 9&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;-&lt;/td&gt;&lt;td align="char" char="." valign="top" rowspan="1" colspan="1"&gt;4751&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;LE-623-10*&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;c.1475G&amp;gt;A&lt;/td&gt;&lt;td align="char" char="." valign="top" colspan="2" rowspan="1"&gt;1247&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;II-1&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Male&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;c.557A&amp;gt;G&lt;/td&gt;&lt;td align="char" char="." valign="top" colspan="2" rowspan="1"&gt;672&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;II-2&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;Female&lt;/td&gt;&lt;td align="left" valign="top" rowspan="1" colspan="1"&gt;c.557A&amp;gt;G&lt;/td&gt;&lt;td align="char" char="." valign="top" colspan="2" rowspan="1"&gt;8294 &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; </infon><infon key="id">T3</infon><infon key="type">table</infon><offset>22143</offset><text>Individual Gender Mutation ANGPT2 plasma concentration (pg/mL)   Control 1 Female - 1690 2196   Control 2 Female - 1197   Control 3 Male - 2354   Control 4 Female - 1729   Control 5 Female - 1419   Control 6 Male - 2297   Control 7 Male - 1479   Control 8 Female - 2844   Control 9 Female - 4751   LE-623-10* Female c.1475G&gt;A 1247   II-1 Male c.557A&gt;G 672   II-2 Female c.557A&gt;G 8294    </text><annotation id="20483"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="22170" length="6" /><text>ANGPT2</text></annotation><annotation id="20484"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="22486" length="8" /><text>c.557A&gt;G</text></annotation><annotation id="20485"><infon key="identifier">tmVar:c|SUB|G|1475|A;HGVS:c.1475G&gt;A;VariantGroup:1;OriginalGene:21687;CorrespondingGene:7010;RS#:769524871;CorrespondingSpecies:10090</infon><infon key="type">DNAMutation</infon><location offset="22459" length="9" /><text>c.1475G&gt;A</text></annotation><annotation id="20486"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="22513" length="8" /><text>c.557A&gt;G</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="type">table_footnote</infon><offset>22551</offset><text>Created by the authors.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="type">table_footnote</infon><offset>22575</offset><text>*Patient previously published. </text><annotation id="20487"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="22576" length="7" /><text>Patient</text></annotation></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="type">table_footnote</infon><offset>22607</offset><text> The mother (II-2) was pregnant at the time of sampling.</text></passage><passage><infon key="section_type">TABLE</infon><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="type">table_footnote</infon><offset>22666</offset><text>ANGPT2, angiopoietin-2.</text><annotation id="20488"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="22666" length="6" /><text>ANGPT2</text></annotation><annotation id="20489"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="22674" length="14" /><text>angiopoietin-2</text></annotation></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>22690</offset><text>Lymphohistochemical staining and placental examination</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>22745</offset><text>No obvious lymphatic abnormalities were noted, possibly due to substantial autolysis, which was present in tissue specimens from the affected fetuses. Placentas from pregnancies III-4 and III-5 were thick and oedematous (table 1). Abnormal maturation of chorionic villi was present in III-5.</text><annotation id="20490"><infon key="identifier">MESH:D044148</infon><infon key="type">Disease</infon><location offset="22756" length="23" /><text>lymphatic abnormalities</text></annotation><annotation id="20491"><infon key="type">Disease</infon><location offset="22954" length="10" /><text>oedematous</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>23037</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23048</offset><text>Two of the authors recently reported heterozygous pathogenic sequence variants in ANGPT2 as a cause of dominantly inherited primary lymphoedema. Here, we report a homozygous variant, NM_001147.2:c.557A&gt;G r.557_566del, in a consanguineous family with recurrent, severe, early-onset hydrops fetalis. The unaffected parents and their two unaffected children are heterozygous and the four affected fetuses homozygous for this LOF variant.</text><annotation id="20492"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="23130" length="6" /><text>ANGPT2</text></annotation><annotation id="20493"><infon key="type">Species</infon><location offset="23231" length="11" /><text>NM_001147.2</text></annotation><annotation id="20494"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="23329" length="15" /><text>hydrops fetalis</text></annotation><annotation id="20495"><infon key="identifier">MESH:D010538</infon><infon key="type">Disease</infon><location offset="23172" length="19" /><text>primary lymphoedema</text></annotation><annotation id="20496"><infon key="identifier">tmVar:c|DEL|557,557_566|G;HGVS:c.557,557_566delG;VariantGroup:11;CorrespondingGene:285;CorrespondingSpecies:9606</infon><infon key="type">DNAMutation</infon><location offset="23243" length="21" /><text>c.557A&gt;G r.557_566del</text></annotation><annotation id="20497"><infon key="identifier">MESH:D006315</infon><infon key="type">Disease</infon><location offset="23470" length="3" /><text>LOF</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>23485</offset><text>ANGPT2 c.557A&gt;G activates a cryptic splice site and prompts nonsense-mediated mRNA decay, NMD/LOF</text><annotation id="20498"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="23485" length="6" /><text>ANGPT2</text></annotation><annotation id="20499"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="23492" length="8" /><text>c.557A&gt;G</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23583</offset><text>Rather than having an effect via an amino acid substitution, the variant activates a cryptic RNA splice site, predicted to remove 10 bp from the coding sequence, leading to a premature stop codon after the third of nine exons, (p.Asp186Valfs*3). Nonsense-mediated mRNA decay results in destruction of this mutant transcript. As confirmed in the unaffected parents, the loss of one allele is reflected by a halving of the expected amount of ANGPT2 plasma protein. ANGPT2 levels in the unaffected heterozygous children have not been assayed as their samples were unavailable. In the homozygous affected fetuses, there was likely a complete absence of ANGPT2 with resultant impaired lymphatic development and severe, lethal hydrops fetalis. Lymphatic dysplasia was not histologically evident in the skin and lung specimens from two affected fetuses. However, at the time of microscopy, autolysis was in process (data not shown). Taken together with earlier reports in humans and the murine model, we nonetheless believe that lymphatic dysplasia is the likely underlying cause of ANGPT2-related fetal hydrops.</text><annotation id="20500"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="24023" length="6" /><text>ANGPT2</text></annotation><annotation id="20501"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="24046" length="6" /><text>ANGPT2</text></annotation><annotation id="20502"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="24232" length="6" /><text>ANGPT2</text></annotation><annotation id="20503"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="24659" length="6" /><text>ANGPT2</text></annotation><annotation id="20504"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="24304" length="15" /><text>hydrops fetalis</text></annotation><annotation id="20505"><infon key="identifier">MESH:C537255</infon><infon key="type">Disease</infon><location offset="24605" length="19" /><text>lymphatic dysplasia</text></annotation><annotation id="20506"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="24563" length="6" /><text>murine</text></annotation><annotation id="20507"><infon key="identifier">tmVar:p|FS|D|186|V|3;HGVS:p.D186VfsX3;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="23811" length="15" /><text>p.Asp186Valfs*3</text></annotation><annotation id="20508"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="24674" length="13" /><text>fetal hydrops</text></annotation><annotation id="20509"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="24548" length="6" /><text>humans</text></annotation><annotation id="20510"><infon key="identifier">MESH:C537255</infon><infon key="type">Disease</infon><location offset="24321" length="19" /><text>Lymphatic dysplasia</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>24691</offset><text>Angpt2 knockout mice have disturbed angiogenetic remodelling</text><annotation id="20511"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="24691" length="6" /><text>Angpt2</text></annotation><annotation id="20512"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="24707" length="4" /><text>mice</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24752</offset><text>The murine knockout mimics the severe phenotype described in this family. In the vascular system, ANGPT2 is considered an antagonist of ANGPT1-induced TIE1-TIE2 (tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 1 and 2) signalling, while it seems to play a comparatively prominent activating role in lymphatic vasculature. Angpt2 knockout mice have normal embryonal vascular development, but disrupted postnatal angiogenic remodelling. In addition, they exhibit major lymphatic vessel defects and generalised lymphatic dysfunction, including chylous ascites. Large lymphatic vessels are replaced by a ragged mesh, and small vessels exhibit abnormal patterning. The lymphatic phenotype, but not the blood vascular remodelling defects appearing later in development, can be rescued by expressing Angpt1 instead of Angpt2 in the Angpt2 locus, showing an activating role of Angpt2 in lymphatics, and in contrast an antagonistic role in blood vessels. ANGPT2 blocking antibodies also affect the formation of button-type lymphatic endothelial cell (LEC) junctions, adherence junction stability or lymphatic valve formation and maturation of collecting lymphatic vessels in mouse embryos. In contrast to the fetuses in our family who died before 27 weeks of gestation, mice homozygous for deletion of Angpt2 were born at normal frequencies, but die from severe chylous ascites and other lymphatic defects by 2 weeks postnatally. Rare mice that survived to adulthood had severe ascites and lymph stasis. </text><annotation id="20513"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="24850" length="6" /><text>ANGPT2</text></annotation><annotation id="20514"><infon key="identifier">11600</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37447</infon><location offset="24888" length="6" /><text>ANGPT1</text></annotation><annotation id="20515"><infon key="identifier">21846</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">3957</infon><location offset="24903" length="4" /><text>TIE1</text></annotation><annotation id="20516"><infon key="identifier">21687</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="24908" length="4" /><text>TIE2</text></annotation><annotation id="20517"><infon key="identifier">7294</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2497</infon><location offset="24914" length="15" /><text>tyrosine kinase</text></annotation><annotation id="20518"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="25108" length="6" /><text>Angpt2</text></annotation><annotation id="20519"><infon key="identifier">11600</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37447</infon><location offset="25579" length="6" /><text>Angpt1</text></annotation><annotation id="20520"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="25597" length="6" /><text>Angpt2</text></annotation><annotation id="20521"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="25611" length="6" /><text>Angpt2</text></annotation><annotation id="20522"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="25655" length="6" /><text>Angpt2</text></annotation><annotation id="20523"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="25732" length="6" /><text>ANGPT2</text></annotation><annotation id="20524"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="26079" length="6" /><text>Angpt2</text></annotation><annotation id="20525"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="26047" length="4" /><text>mice</text></annotation><annotation id="20526"><infon key="identifier">MESH:D008206</infon><infon key="type">Disease</infon><location offset="25294" length="21" /><text>lymphatic dysfunction</text></annotation><annotation id="20527"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="25124" length="4" /><text>mice</text></annotation><annotation id="20528"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="25952" length="5" /><text>mouse</text></annotation><annotation id="20529"><infon key="identifier">MESH:D014647</infon><infon key="type">Disease</infon><location offset="26267" length="12" /><text>lymph stasis</text></annotation><annotation id="20530"><infon key="identifier">MESH:D066253</infon><infon key="type">Disease</infon><location offset="25483" length="26" /><text>blood vascular remodelling</text></annotation><annotation id="20531"><infon key="identifier">MESH:D044148</infon><infon key="type">Disease</infon><location offset="26165" length="17" /><text>lymphatic defects</text></annotation><annotation id="20532"><infon key="identifier">MESH:D002915</infon><infon key="type">Disease</infon><location offset="25327" length="15" /><text>chylous ascites</text></annotation><annotation id="20533"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="24756" length="6" /><text>murine</text></annotation><annotation id="20534"><infon key="identifier">MESH:D018190</infon><infon key="type">Disease</infon><location offset="25253" length="24" /><text>lymphatic vessel defects</text></annotation><annotation id="20535"><infon key="identifier">MESH:D002915</infon><infon key="type">Disease</infon><location offset="26139" length="15" /><text>chylous ascites</text></annotation><annotation id="20536"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="26212" length="4" /><text>mice</text></annotation><annotation id="20537"><infon key="identifier">MESH:D001201</infon><infon key="type">Disease</infon><location offset="26255" length="7" /><text>ascites</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>26284</offset><text>Heterozygous ANGPT2 LOF mutations cause mild congenital lymphoedema</text><annotation id="20538"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="26297" length="6" /><text>ANGPT2</text></annotation><annotation id="20539"><infon key="identifier">MESH:D008209</infon><infon key="type">Disease</infon><location offset="26329" length="22" /><text>congenital lymphoedema</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>26352</offset><text>In the original report of seven affected individuals from five families with heterozygous ANGPT2 mutations, the disorder was characterised by mild lymphoedema in early life, with resolution in three individuals during the first months after birth or adolescence and reduced penetrance in two unaffected mutation carriers. A heterozygous whole-gene deletion was identified in a 1.5-year-old boy followed for lower leg oedemas first noted at age 8-9 weeks. Three reported amino acid substitutions (Asn304Lys, Cys435Ser and Arg492Gln) resulted in LOF together with partially inhibited secretion of the WT allele in vitro, which may have a partial dominant-negative effect on ANGPT2 signalling. Variable effects on ANGPT2 are further exemplified by a fifth mutation (Thr299Met) that leads to gain-of-function, inducing increased lymphatic proliferation when expressed in the mouse ear. The associated clinical phenotype was progressive, hypothesised to be due to hyperplasia. However, genotype-phenotype correlations are tentative due to the low number of cases. These results indicate an optimal window of activity for ANGPT2, from which deviation upwards or downwards may significantly hamper development of lymphatic vasculature.</text><annotation id="20540"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="26442" length="6" /><text>ANGPT2</text></annotation><annotation id="20541"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="27024" length="6" /><text>ANGPT2</text></annotation><annotation id="20542"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="27063" length="6" /><text>ANGPT2</text></annotation><annotation id="20543"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="27468" length="6" /><text>ANGPT2</text></annotation><annotation id="20544"><infon key="identifier">tmVar:p|SUB|N|304|K;HGVS:p.N304K;VariantGroup:9;OriginalGene:11601;CorrespondingGene:285;RS#:767462360;CorrespondingSpecies:10090</infon><infon key="type">ProteinMutation</infon><location offset="26848" length="9" /><text>Asn304Lys</text></annotation><annotation id="20545"><infon key="identifier">tmVar:p|SUB|T|299|M;HGVS:p.T299M;VariantGroup:10;OriginalGene:11601;CorrespondingGene:285;RS#:61733318;CorrespondingSpecies:10090;CA#:4611142</infon><infon key="type">ProteinMutation</infon><location offset="27115" length="9" /><text>Thr299Met</text></annotation><annotation id="20546"><infon key="type">Disease</infon><location offset="26499" length="11" /><text>lymphoedema</text></annotation><annotation id="20547"><infon key="identifier">MESH:D006315</infon><infon key="type">Disease</infon><location offset="26896" length="3" /><text>LOF</text></annotation><annotation id="20548"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="27223" length="5" /><text>mouse</text></annotation><annotation id="20549"><infon key="identifier">MESH:C536897</infon><infon key="type">Disease</infon><location offset="26759" length="17" /><text>lower leg oedemas</text></annotation><annotation id="20550"><infon key="identifier">tmVar:p|SUB|C|435|S;HGVS:p.C435S;VariantGroup:13;CorrespondingGene:285;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="26859" length="9" /><text>Cys435Ser</text></annotation><annotation id="20551"><infon key="identifier">MESH:D006965</infon><infon key="type">Disease</infon><location offset="27311" length="11" /><text>hyperplasia</text></annotation><annotation id="20552"><infon key="identifier">tmVar:p|SUB|R|492|Q;HGVS:p.R492Q;VariantGroup:23;CorrespondingGene:9644;RS#:759640059;CorrespondingSpecies:9606</infon><infon key="type">ProteinMutation</infon><location offset="26873" length="9" /><text>Arg492Gln</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>27585</offset><text>Is there a lymphoedema phenotype in c.557A&gt;G heterozygotes?</text><annotation id="20553"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="27621" length="8" /><text>c.557A&gt;G</text></annotation><annotation id="20554"><infon key="type">Disease</infon><location offset="27596" length="11" /><text>lymphoedema</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>27645</offset><text>Heterozygosity for c.557A&gt;G causes haploinsufficiency, and we aimed to delineate the phenotype of the heterozygotes in our family. In individual III-9, significantly increased nuchal translucency was detected on ultrasound at week 12 but was completely resolved 2 weeks later. Pregnancy was monitored closely, and there were no other signs of oedema in the fetus or the mother. The healthy newborn boy was not oedematous, and no oedemas developed by age 12 months. Heterozygosity for the pathogenic sequence variant might explain his transiently and significantly increased nuchal translucency; no other likely cause was found. Indeed, one of the individuals reported by Leppanen et al  also had increased nuchal translucency early in pregnancy. In our family, there is no evidence of primary lymphoedema in the heterozygous child nor in the parents, although pregnancy and neonatal records were not available for all. Thus, postnatal transient lymphoedema cannot be excluded. Furthermore, genetic predisposition may play a role when secondary lymphoedema develops in other contexts, for example, after surgery for breast cancer. Cellulitis is a well-recognised complication of primary lymphoedema. Whether or not clinically unaffected heterozygotes for a pathogenic ANGPT2 variant are at increased risk of secondary lymphoedema and subsequently for cellulitis is not known.</text><annotation id="20555"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="28912" length="6" /><text>ANGPT2</text></annotation><annotation id="20556"><infon key="identifier">MESH:C536897</infon><infon key="type">Disease</infon><location offset="27988" length="6" /><text>oedema</text></annotation><annotation id="20557"><infon key="type">Disease</infon><location offset="28962" length="11" /><text>lymphoedema</text></annotation><annotation id="20558"><infon key="identifier">MESH:D002481</infon><infon key="type">Disease</infon><location offset="28775" length="10" /><text>Cellulitis</text></annotation><annotation id="20559"><infon key="type">Disease</infon><location offset="28689" length="11" /><text>lymphoedema</text></annotation><annotation id="20560"><infon key="type">Disease</infon><location offset="28590" length="11" /><text>lymphoedema</text></annotation><annotation id="20561"><infon key="identifier">MESH:C536897</infon><infon key="type">Disease</infon><location offset="28074" length="7" /><text>oedemas</text></annotation><annotation id="20562"><infon key="identifier">MESH:D010538</infon><infon key="type">Disease</infon><location offset="28430" length="19" /><text>primary lymphoedema</text></annotation><annotation id="20563"><infon key="identifier">MESH:D010538</infon><infon key="type">Disease</infon><location offset="28823" length="19" /><text>primary lymphoedema</text></annotation><annotation id="20564"><infon key="type">Disease</infon><location offset="28055" length="10" /><text>oedematous</text></annotation><annotation id="20565"><infon key="identifier">MESH:D001943</infon><infon key="type">Disease</infon><location offset="28760" length="13" /><text>breast cancer</text></annotation><annotation id="20566"><infon key="identifier">tmVar:c|SUB|A|557|G;HGVS:c.557A&gt;G;VariantGroup:3;CorrespondingGene:1557;RS#:140278421;CorrespondingSpecies:9606;CA#:5616484</infon><infon key="type">DNAMutation</infon><location offset="27664" length="8" /><text>c.557A&gt;G</text></annotation><annotation id="20567"><infon key="identifier">MESH:D002481</infon><infon key="type">Disease</infon><location offset="28995" length="10" /><text>cellulitis</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>29023</offset><text>What is the cause of lymphoedema in individual II-6?</text><annotation id="20568"><infon key="type">Disease</infon><location offset="29044" length="11" /><text>lymphoedema</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29076</offset><text>Lymphoscintigraphy of individual II-6 revealed lower extremity lymphoedema, abnormal morphology of lymphatic vessels in the right leg and absence of detectable lymphatic vessels in the left leg. Sanger sequencing of two separate blood samples and targeted NGS failed to identify the likely pathogenic variant in ANGPT2 or any likely pathogenic variant in primary lymphoedema genes. Thus, the cause of her lymphoedema remains unknown.</text><annotation id="20569"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="29388" length="6" /><text>ANGPT2</text></annotation><annotation id="20570"><infon key="type">Disease</infon><location offset="29481" length="11" /><text>lymphoedema</text></annotation><annotation id="20571"><infon key="type">Disease</infon><location offset="29439" length="11" /><text>lymphoedema</text></annotation><annotation id="20572"><infon key="identifier">MESH:C563475</infon><infon key="type">Disease</infon><location offset="29129" length="21" /><text>extremity lymphoedema</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>29510</offset><text>Phenotype in the affected fetuses</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29544</offset><text>This family demonstrates uniquely the natural course of complete LOF of ANGPT2 in humans. With one exception, the affected pregnancies were not terminated, but monitored until fetal demise. All three affected fetuses, for which a nuchal translucency measurement in the first trimester was available (III-5, III-7 and III-8), showed increased values, approaching what is seen in nuchal lymphatic malformations (cystic hygromas). Progression of hydrops was gradual from increased nuchal translucency to cystic hygroma, extensive subcutaneous fluid accumulation, hydrothorax, and lastly ascites, with intrauterine death occurring between weeks 14 and 27. The significantly, but transiently, increased nuchal translucency in a heterozygous unaffected fetus (III-9) underscores the importance of repeated ultrasounds in the context of increased nuchal translucency of unknown cause. We noted no specific feature that distinguishes ANGPT2-related hydrops from other forms of NIHF.</text><annotation id="20573"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="29616" length="6" /><text>ANGPT2</text></annotation><annotation id="20574"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="30470" length="6" /><text>ANGPT2</text></annotation><annotation id="20575"><infon key="identifier">MESH:D008209</infon><infon key="type">Disease</infon><location offset="29922" length="30" /><text>nuchal lymphatic malformations</text></annotation><annotation id="20576"><infon key="identifier">MESH:D018191</infon><infon key="type">Disease</infon><location offset="29954" length="15" /><text>cystic hygromas</text></annotation><annotation id="20577"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="29626" length="6" /><text>humans</text></annotation><annotation id="20578"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="30513" length="4" /><text>NIHF</text></annotation><annotation id="20579"><infon key="identifier">MESH:D001201</infon><infon key="type">Disease</infon><location offset="30128" length="7" /><text>ascites</text></annotation><annotation id="20580"><infon key="identifier">MESH:D003643</infon><infon key="type">Disease</infon><location offset="30142" length="18" /><text>intrauterine death</text></annotation><annotation id="20581"><infon key="identifier">MESH:D006876</infon><infon key="type">Disease</infon><location offset="30104" length="11" /><text>hydrothorax</text></annotation><annotation id="20582"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="29987" length="7" /><text>hydrops</text></annotation><annotation id="20583"><infon key="identifier">MESH:D004487</infon><infon key="type">Disease</infon><location offset="30485" length="7" /><text>hydrops</text></annotation><annotation id="20584"><infon key="identifier">MESH:D006315</infon><infon key="type">Disease</infon><location offset="29609" length="3" /><text>LOF</text></annotation><annotation id="20585"><infon key="identifier">MESH:D018191</infon><infon key="type">Disease</infon><location offset="30052" length="7" /><text>hygroma</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>30519</offset><text>Additional phenotypic features in the homozygous fetuses</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>30576</offset><text>Fetus III-4 had tetralogy of Fallot and fetus III-5 had a structurally normal heart. Two fetuses (III-7 and III-8) died too early to allow thorough assessment of cardiac anatomy. In a large cohort of individuals with tetralogy of Fallot, there was no increased burden of rare variants in ANGPT2 (K Devriendt, MD, personal communication, December 2020). Thus, it is unclear whether congenital heart malformations are a feature of the homozygous ANGPT2 phenotype. WES of fetus III-4 did not reveal any other pathogenic or likely pathogenic variants in genes known to be associated with tetralogy of Fallot.</text><annotation id="20586"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="30864" length="6" /><text>ANGPT2</text></annotation><annotation id="20587"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="31020" length="6" /><text>ANGPT2</text></annotation><annotation id="20588"><infon key="identifier">MESH:D013771</infon><infon key="type">Disease</infon><location offset="30592" length="19" /><text>tetralogy of Fallot</text></annotation><annotation id="20589"><infon key="identifier">MESH:D013771</infon><infon key="type">Disease</infon><location offset="31160" length="19" /><text>tetralogy of Fallot</text></annotation><annotation id="20590"><infon key="identifier">MESH:D013771</infon><infon key="type">Disease</infon><location offset="30793" length="19" /><text>tetralogy of Fallot</text></annotation><annotation id="20591"><infon key="identifier">MESH:D006330</infon><infon key="type">Disease</infon><location offset="30957" length="30" /><text>congenital heart malformations</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>31181</offset><text>Fetus III-5 revealed short long bones radiographically. This could have been due to general growth retardation via placental dysfunction or more specifically related to vascular/lymphatic abnormalities.</text><annotation id="20592"><infon key="identifier">MESH:D006130</infon><infon key="type">Disease</infon><location offset="31273" length="18" /><text>growth retardation</text></annotation><annotation id="20593"><infon key="identifier">MESH:D010922</infon><infon key="type">Disease</infon><location offset="31296" length="21" /><text>placental dysfunction</text></annotation><annotation id="20594"><infon key="identifier">MESH:D044148</infon><infon key="type">Disease</infon><location offset="31350" length="32" /><text>vascular/lymphatic abnormalities</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>31384</offset><text>Fetus III-4 was probably growth retarded given the 2-week discrepancy between estimated due date based on last menstrual period versus sonographic estimation of gestational age. The length of the long bones was not commented on autopsy.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>31621</offset><text>ANGPT2 biallelic variants: a rare cause of hydrops fetalis</text><annotation id="20595"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="31621" length="6" /><text>ANGPT2</text></annotation><annotation id="20596"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="31664" length="15" /><text>hydrops fetalis</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>31680</offset><text>Biallelic LOF variants are likely a rare cause of recessive lymphatic-related hydrops fetalis. We are not aware of any other biallelic ANGPT2 LOF variants in other cohorts of fetal hydrops to date, and no other match for ANGPT2 was identified via GeneMatcher. The condition seems to be very severe, perhaps even universally lethal. Other cases may remain undiagnosed due to early fetal demise in the absence of molecular genetic investigations, as suggested by Quinn et al. In the same signalling pathway as ANGPT2, other genes have known phenotypes related to inherited monoallelic or somatic variants. Somatic and constitutional variants in the TIE2-encoding gene TEK cause venous malformations via a gain-of-function mechanism, while constitutional LOF variants may underlie primary congenital glaucoma. ANGPT1 variants are reported in primary congenital glaucoma and hereditary angio-oedema. Homozygous LOF of ANGPT1 and TEK is expected to be embryonically lethal in humans, as in mice, due to defective blood vessel formation, but not expected to cause fetal hydrops.</text><annotation id="20597"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="31815" length="6" /><text>ANGPT2</text></annotation><annotation id="20598"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="31901" length="6" /><text>ANGPT2</text></annotation><annotation id="20599"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="32188" length="6" /><text>ANGPT2</text></annotation><annotation id="20600"><infon key="identifier">7010</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="32327" length="4" /><text>TIE2</text></annotation><annotation id="20601"><infon key="identifier">7010</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="32346" length="3" /><text>TEK</text></annotation><annotation id="20602"><infon key="identifier">284</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37447</infon><location offset="32487" length="6" /><text>ANGPT1</text></annotation><annotation id="20603"><infon key="identifier">284</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37447</infon><location offset="32594" length="6" /><text>ANGPT1</text></annotation><annotation id="20604"><infon key="identifier">21687</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="32605" length="3" /><text>TEK</text></annotation><annotation id="20605"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="32738" length="13" /><text>fetal hydrops</text></annotation><annotation id="20606"><infon key="identifier">MESH:D009386</infon><infon key="type">Disease</infon><location offset="32551" length="23" /><text>hereditary angio-oedema</text></annotation><annotation id="20607"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="31855" length="13" /><text>fetal hydrops</text></annotation><annotation id="20608"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="31730" length="43" /><text>recessive lymphatic-related hydrops fetalis</text></annotation><annotation id="20609"><infon key="identifier">MESH:C565547</infon><infon key="type">Disease</infon><location offset="32519" length="27" /><text>primary congenital glaucoma</text></annotation><annotation id="20610"><infon key="identifier">MESH:C565547</infon><infon key="type">Disease</infon><location offset="32458" length="27" /><text>primary congenital glaucoma</text></annotation><annotation id="20611"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="32665" length="4" /><text>mice</text></annotation><annotation id="20612"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="32651" length="6" /><text>humans</text></annotation><annotation id="20613"><infon key="identifier">MESH:C563977</infon><infon key="type">Disease</infon><location offset="32356" length="20" /><text>venous malformations</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>32753</offset><text>WES in the diagnostic work-up of NIHF</text><annotation id="20614"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="32786" length="4" /><text>NIHF</text></annotation></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>32791</offset><text>The Society for Maternal-Fetal Medicine's guidelines for the diagnostic work-up of NIHF from 2015 does not address testing for monogenic disorders. However, given the rapid identification of new single gene disorders, WES is recommended as the preferred sequencing approach for NIHF. The likelihood of identifying new disease genes via single cases is high given the severity and decreased viability of the phenotype, as in this family.</text><annotation id="20615"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="32874" length="4" /><text>NIHF</text></annotation><annotation id="20616"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="33069" length="4" /><text>NIHF</text></annotation><annotation id="20617"><infon key="identifier">MESH:D009358</infon><infon key="type">Disease</infon><location offset="32918" length="19" /><text>monogenic disorders</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>33230</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>33241</offset><text>In conclusion, we report the first family with severe, early-onset hydrops fetalis caused by a homozygous LOF variant in ANGPT2. Our findings are in accordance with the previous identification of heterozygous missense variants causing autosomal dominant primary lymphoedema and with the crucial role of ANGPT2 in lymphatic development demonstrated by the murine knockout model. Biallelic ANGPT2 LOF is yet another of the many monogenic causes of NIHF. Subsequent studies may be able to confirm our suspicion of an underlying generalised lymphatic dysplasia. Heterozygous carriers of LOF variants may manifest signs of lymphatic insufficiency, such as dependent lymphoedema or transiently increased fetal nuchal translucency in early pregnancy.</text><annotation id="20618"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="33362" length="6" /><text>ANGPT2</text></annotation><annotation id="20619"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="33544" length="6" /><text>ANGPT2</text></annotation><annotation id="20620"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="33629" length="6" /><text>ANGPT2</text></annotation><annotation id="20621"><infon key="identifier">MESH:D010538</infon><infon key="type">Disease</infon><location offset="33495" length="19" /><text>primary lymphoedema</text></annotation><annotation id="20622"><infon key="identifier">MESH:C537255</infon><infon key="type">Disease</infon><location offset="33778" length="19" /><text>lymphatic dysplasia</text></annotation><annotation id="20623"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="33308" length="15" /><text>hydrops fetalis</text></annotation><annotation id="20624"><infon key="identifier">MESH:D000309</infon><infon key="type">Disease</infon><location offset="33859" length="23" /><text>lymphatic insufficiency</text></annotation><annotation id="20625"><infon key="identifier">MESH:D006315</infon><infon key="type">Disease</infon><location offset="33636" length="3" /><text>LOF</text></annotation><annotation id="20626"><infon key="identifier">10090</infon><infon key="type">Species</infon><location offset="33596" length="6" /><text>murine</text></annotation><annotation id="20627"><infon key="identifier">MESH:D019966</infon><infon key="type">Disease</infon><location offset="33892" length="21" /><text>dependent lymphoedema</text></annotation><annotation id="20628"><infon key="identifier">MESH:D015160</infon><infon key="type">Disease</infon><location offset="33687" length="4" /><text>NIHF</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>33985</offset><text>Twitter: @MiikkaVikkula</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>34009</offset><text>Correction notice: This article has been corrected since it was published online first. The gene name in the title has been italicised.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>34145</offset><text>Contributors: All authors of this manuscript fulfill the criteria for authorship. PB and OLH performed molecular studies. MFS, BH, LMB and CVN conducted clinical investigations and collected patient samples. PB, MFS, TP, OLH, MN, CVN and MV planned the study. PB, MFS, TP, OLH, MN, BH and MV wrote the manuscript. All authors revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript. OLH is responsible for the overall content as guarantor.</text><annotation id="20629"><infon key="identifier">642</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">330</infon><location offset="34272" length="2" /><text>BH</text></annotation><annotation id="20630"><infon key="identifier">642</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">330</infon><location offset="34427" length="2" /><text>BH</text></annotation><annotation id="20631"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="34336" length="7" /><text>patient</text></annotation><annotation id="20632"><infon key="type">Disease</infon><location offset="34234" length="3" /><text>OLH</text></annotation><annotation id="20633"><infon key="type">Disease</infon><location offset="34284" length="3" /><text>CVN</text></annotation><annotation id="20634"><infon key="type">Disease</infon><location offset="34375" length="3" /><text>CVN</text></annotation></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>34654</offset><text>Funding: The work in Brussels was funded by the FRS-FNRS (Fonds de la Recherche Scientifique, Belgium) (grants T.0026.14 and T.0247.19), the Fund Generet managed by the King Baudouin Foundation (2018-J1810250-211305) (Belgium), and the Walloon Excellence in Lifesciences and Biotechnology (FNRS-WELBIO; WELBIO-CR-2019C).</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>34975</offset><text>Competing interests: PB has received support from Belgian Fonds de la Recherche Scientifique for attending meetings and/or travel.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>35106</offset><text>Provenance and peer review: Not commissioned; externally peer reviewed.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>35178</offset><text>Data availability statement</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>35206</offset><text>All data relevant to the study are included in the article or uploaded as supplementary information.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>35307</offset><text>Ethics statements</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_2</infon><offset>35325</offset><text>Patient consent for publication</text><annotation id="20635"><infon key="identifier">9606</infon><infon key="type">Species</infon><location offset="35325" length="7" /><text>Patient</text></annotation></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>35357</offset><text>Parental/guardian consent obtained.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_2</infon><offset>35393</offset><text>Ethics approval</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>35409</offset><text>The parents provided informed, written consent on behalf of themselves, their children and fetuses, as did the maternal aunt for inclusion in the study and for publication of clinical information, results of laboratory investigations and photographs, in accordance with IRB approval from the University of Louvain, Brussels, Belgium (B403201629786). Initial investigations were performed in a diagnostic setting.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>35822</offset><text>References</text></passage><passage><infon key="volume">158A</infon><infon key="section_type">REF</infon><infon key="fpage">597</infon><infon key="pub-id_doi">10.1002/ajmg.a.34438</infon><infon key="pub-id_pmid">22302731</infon><infon key="year">2012</infon><infon key="source">Am J Med Genet A</infon><infon key="type">ref</infon><infon key="lpage">605</infon><offset>35833</offset><text>Non-Immune hydrops fetalis: a short review of etiology and pathophysiology</text></passage><passage><infon key="volume">56</infon><infon key="section_type">REF</infon><infon key="fpage">416</infon><infon key="pub-id_doi">10.1002/uog.22019</infon><infon key="pub-id_pmid">32196790</infon><infon key="year">2020</infon><infon key="source">Ultrasound Obstet Gynecol</infon><infon key="type">ref</infon><infon key="lpage">21</infon><offset>35908</offset><text>Non-Immune fetal hydrops: etiology and outcome according to gestational age at diagnosis</text></passage><passage><infon key="volume">212</infon><infon key="section_type">REF</infon><infon key="fpage">127</infon><infon key="pub-id_doi">10.1016/j.ajog.2014.12.018</infon><infon key="pub-id_pmid">25557883</infon><infon key="year">2015</infon><infon key="source">Am J Obstet Gynecol</infon><infon key="type">ref</infon><infon key="lpage">39</infon><offset>35997</offset><text>Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis</text></passage><passage><infon key="section_type">REF</infon><infon key="year">2020</infon><infon key="type">ref</infon><offset>36089</offset><text>Nonimmune hydrops fetalis Waltham, MA: UpToDate</text></passage><passage><infon key="volume">79</infon><infon key="section_type">REF</infon><infon key="fpage">256</infon><infon key="pub-id_pmid">1731295</infon><infon key="year">1992</infon><infon key="source">Obstet Gynecol</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>36137</offset><text>Antenatal classification of hydrops fetalis</text></passage><passage><infon key="volume">24</infon><infon key="section_type">REF</infon><infon key="fpage">258</infon><infon key="pub-id_doi">10.3109/14767058.2010.483522</infon><infon key="pub-id_pmid">20446894</infon><infon key="year">2011</infon><infon key="source">J Matern Fetal Neonatal Med</infon><infon key="type">ref</infon><infon key="lpage">63</infon><offset>36181</offset><text>Hydrops fetalis--has there been a change in diagnostic spectrum and mortality?</text></passage><passage><infon key="volume">149A</infon><infon key="section_type">REF</infon><infon key="fpage">852</infon><infon key="pub-id_doi">10.1002/ajmg.a.32677</infon><infon key="pub-id_pmid">19334092</infon><infon key="year">2009</infon><infon key="source">Am J Med Genet A</infon><infon key="type">ref</infon><infon key="lpage">3</infon><offset>36260</offset><text>A diagnostic flow chart for non-immune hydrops fetalis</text></passage><passage><infon key="volume">167A</infon><infon key="section_type">REF</infon><infon key="fpage">1082</infon><infon key="pub-id_doi">10.1002/ajmg.a.36988</infon><infon key="pub-id_pmid">25712632</infon><infon key="year">2015</infon><infon key="source">Am J Med Genet A</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>36315</offset><text>Etiology of non-immune hydrops fetalis: an update</text></passage><passage><infon key="volume">38</infon><infon key="section_type">REF</infon><infon key="fpage">337</infon><infon key="pub-id_doi">10.1002/pd.5243</infon><infon key="pub-id_pmid">29500832</infon><infon key="year">2018</infon><infon key="source">Prenat Diagn</infon><infon key="type">ref</infon><infon key="lpage">43</infon><offset>36365</offset><text>Improved diagnosis in nonimmune hydrops fetalis using a standardized algorithm</text></passage><passage><infon key="volume">383</infon><infon key="section_type">REF</infon><infon key="fpage">1746</infon><infon key="pub-id_doi">10.1056/NEJMoa2023643</infon><infon key="pub-id_pmid">33027564</infon><infon key="year">2020</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="lpage">56</infon><offset>36444</offset><text>Exome sequencing for prenatal diagnosis in nonimmune hydrops fetalis</text></passage><passage><infon key="volume">23</infon><infon key="section_type">REF</infon><infon key="pub-id_doi">10.1038/s41436-020-00967-0</infon><infon key="year">2021</infon><infon key="source">Genet Med</infon><infon key="type">ref</infon><offset>36513</offset><text>A systematic review of monogenic etiologies of nonimmune hydrops fetalis</text></passage><passage><infon key="volume">57</infon><infon key="section_type">REF</infon><infon key="fpage">653</infon><infon key="pub-id_doi">10.1136/jmedgenet-2019-106084</infon><infon key="pub-id_pmid">32409509</infon><infon key="year">2020</infon><infon key="source">J Med Genet</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>36586</offset><text>Update and audit of the St George's classification algorithm of primary lymphatic anomalies: a clinical and molecular approach to diagnosis</text></passage><passage><infon key="volume">51</infon><infon key="section_type">REF</infon><infon key="fpage">1560</infon><infon key="pub-id_doi">10.1038/s41588-019-0528-2</infon><infon key="pub-id_pmid">31676867</infon><infon key="year">2019</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="lpage">5</infon><offset>36726</offset><text>PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels</text></passage><passage><infon key="volume">25</infon><infon key="section_type">REF</infon><infon key="fpage">153</infon><infon key="pub-id_doi">10.1038/75997</infon><infon key="pub-id_pmid">10835628</infon><infon key="year">2000</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="lpage">9</infon><offset>36811</offset><text>Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema</text></passage><passage><infon key="volume">67</infon><infon key="section_type">REF</infon><infon key="fpage">295</infon><infon key="pub-id_doi">10.1086/303019</infon><infon key="pub-id_pmid">10856194</infon><infon key="year">2000</infon><infon key="source">Am J Hum Genet</infon><infon key="type">ref</infon><infon key="lpage">301</infon><offset>36887</offset><text>Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase</text><annotation id="20636"><infon key="identifier">2324</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">7321</infon><location offset="36958" length="6" /><text>VEGFR3</text></annotation></passage><passage><infon key="volume">124</infon><infon key="section_type">REF</infon><infon key="fpage">898</infon><infon key="pub-id_doi">10.1172/JCI71614</infon><infon key="pub-id_pmid">24590274</infon><infon key="year">2014</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="lpage">904</infon><offset>36981</offset><text>Genetics of lymphatic anomalies</text></passage><passage><infon key="volume">26</infon><infon key="section_type">REF</infon><infon key="fpage">4095</infon><infon key="pub-id_doi">10.1093/hmg/ddx297</infon><infon key="pub-id_pmid">28985353</infon><infon key="year">2017</infon><infon key="source">Hum Mol Genet</infon><infon key="type">ref</infon><infon key="lpage">104</infon><offset>37013</offset><text>Loss of ADAMTS3 activity causes Hennekam lymphangiectasia-lymphedema syndrome 3</text><annotation id="20637"><infon key="identifier">9508</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">8596</infon><location offset="37021" length="7" /><text>ADAMTS3</text></annotation></passage><passage><infon key="volume">182</infon><infon key="section_type">REF</infon><infon key="fpage">189</infon><infon key="pub-id_doi">10.1002/ajmg.a.61392</infon><infon key="pub-id_pmid">31633297</infon><infon key="year">2020</infon><infon key="source">Am J Med Genet A</infon><infon key="type">ref</infon><infon key="lpage">94</infon><offset>37093</offset><text>Biallelic mutation of Fbxl7 suggests a novel form of Hennekam syndrome</text><annotation id="20638"><infon key="identifier">23194</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">69121</infon><location offset="37115" length="5" /><text>Fbxl7</text></annotation></passage><passage><infon key="volume">25</infon><infon key="section_type">REF</infon><infon key="fpage">1116</infon><infon key="pub-id_doi">10.1038/s41591-019-0479-2</infon><infon key="pub-id_pmid">31263281</infon><infon key="year">2019</infon><infon key="source">Nat Med</infon><infon key="type">ref</infon><infon key="lpage">22</infon><offset>37164</offset><text>ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor</text><annotation id="20639"><infon key="identifier">369</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">1249</infon><location offset="37164" length="4" /><text>ARAF</text></annotation></passage><passage><infon key="volume">6</infon><infon key="section_type">REF</infon><infon key="pub-id_doi">10.1038/ncomms9085</infon><infon key="pub-id_pmid">26333996</infon><infon key="year">2015</infon><infon key="source">Nat Commun</infon><infon key="type">ref</infon><infon key="elocation-id">8085</infon><offset>37263</offset><text>Novel mutations in Piezo1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis</text><annotation id="20640"><infon key="identifier">9780</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">124356</infon><location offset="37282" length="6" /><text>Piezo1</text></annotation></passage><passage><infon key="volume">126</infon><infon key="section_type">REF</infon><infon key="fpage">3080</infon><infon key="pub-id_doi">10.1172/JCI85794</infon><infon key="pub-id_pmid">27400125</infon><infon key="year">2016</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>37382</offset><text>Ephb4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis</text><annotation id="20641"><infon key="identifier">2050</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">20939</infon><location offset="37382" length="5" /><text>Ephb4</text></annotation></passage><passage><infon key="volume">215</infon><infon key="section_type">REF</infon><infon key="fpage">2339</infon><infon key="pub-id_doi">10.1084/jem.20180528</infon><infon key="pub-id_pmid">30115739</infon><infon key="year">2018</infon><infon key="source">J Exp Med</infon><infon key="type">ref</infon><infon key="lpage">53</infon><offset>37477</offset><text>hCALCRL mutation causes autosomal recessive nonimmune hydrops fetalis with lymphatic dysplasia</text></passage><passage><infon key="volume">182</infon><infon key="section_type">REF</infon><infon key="fpage">2152</infon><infon key="pub-id_doi">10.1002/ajmg.a.61743</infon><infon key="pub-id_pmid">32618121</infon><infon key="year">2020</infon><infon key="source">Am J Med Genet A</infon><infon key="type">ref</infon><infon key="lpage">60</infon><offset>37572</offset><text>A homozygous variant in growth and differentiation factor 2 (GDF2) may cause lymphatic dysplasia with hydrothorax and nonimmune hydrops fetalis</text><annotation id="20642"><infon key="identifier">2658</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">32299</infon><location offset="37633" length="4" /><text>GDF2</text></annotation></passage><passage><infon key="volume">12</infon><infon key="section_type">REF</infon><infon key="pub-id_doi">10.1126/scitranslmed.aax8013</infon><infon key="year">2020</infon><infon key="comment">09 Sep 2020</infon><infon key="source">Sci Transl Med</infon><infon key="type">ref</infon><offset>37716</offset><text>Characterization of ANGPT2 mutations associated with primary lymphedema</text><annotation id="20643"><infon key="identifier">11601</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="37736" length="6" /><text>ANGPT2</text></annotation></passage><passage><infon key="volume">277</infon><infon key="section_type">REF</infon><infon key="fpage">55</infon><infon key="pub-id_doi">10.1126/science.277.5322.55</infon><infon key="pub-id_pmid">9204896</infon><infon key="year">1997</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="lpage">60</infon><offset>37788</offset><text>Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis</text><annotation id="20644"><infon key="identifier">7010</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="37829" length="4" /><text>Tie2</text></annotation><annotation id="20645"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="37788" length="14" /><text>Angiopoietin-2</text></annotation></passage><passage><infon key="volume">3</infon><infon key="section_type">REF</infon><infon key="fpage">411</infon><infon key="pub-id_doi">10.1016/S1534-5807(02)00217-4</infon><infon key="pub-id_pmid">12361603</infon><infon key="year">2002</infon><infon key="source">Dev Cell</infon><infon key="type">ref</infon><infon key="lpage">23</infon><offset>37869</offset><text>Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1</text><annotation id="20646"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="37869" length="14" /><text>Angiopoietin-2</text></annotation></passage><passage><infon key="volume">43</infon><infon key="section_type">REF</infon><infon key="fpage">491</infon><infon key="pub-id_doi">10.1038/ng.806</infon><infon key="pub-id_pmid">21478889</infon><infon key="year">2011</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>38003</offset><text>A framework for variation discovery and genotyping using next-generation DNA sequencing data</text></passage><passage><infon key="volume">38</infon><infon key="section_type">REF</infon><infon key="pub-id_doi">10.1093/nar/gkq603</infon><infon key="pub-id_pmid">20601685</infon><infon key="year">2010</infon><infon key="source">Nucleic Acids Res</infon><infon key="type">ref</infon><infon key="elocation-id">e164</infon><offset>38096</offset><text>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data</text></passage><passage><infon key="volume">32</infon><infon key="section_type">REF</infon><infon key="fpage">1592</infon><infon key="pub-id_doi">10.1093/bioinformatics/btw046</infon><infon key="pub-id_pmid">26819469</infon><infon key="year">2016</infon><infon key="source">Bioinformatics</infon><infon key="type">ref</infon><infon key="lpage">4</infon><offset>38184</offset><text>FILTUS: a desktop Gui for fast and efficient detection of disease-causing variants, including a novel autozygosity detector</text></passage><passage><infon key="volume">14</infon><infon key="section_type">REF</infon><infon key="fpage">178</infon><infon key="pub-id_doi">10.1093/bib/bbs017</infon><infon key="pub-id_pmid">22517427</infon><infon key="year">2013</infon><infon key="source">Brief Bioinform</infon><infon key="type">ref</infon><infon key="lpage">92</infon><offset>38308</offset><text>Integrative genomics Viewer (IGV): high-performance genomics data visualization and exploration</text></passage><passage><infon key="volume">36</infon><infon key="section_type">REF</infon><infon key="fpage">928</infon><infon key="pub-id_doi">10.1002/humu.22844</infon><infon key="pub-id_pmid">26220891</infon><infon key="year">2015</infon><infon key="source">Hum Mutat</infon><infon key="type">ref</infon><infon key="lpage">30</infon><offset>38404</offset><text>GeneMatcher: a matching tool for connecting Investigators with an interest in the same gene</text></passage><passage><infon key="volume">18</infon><infon key="section_type">REF</infon><infon key="fpage">1181</infon><infon key="pub-id_doi">10.1016/j.amjhyper.2005.03.745</infon><infon key="pub-id_pmid">16182107</infon><infon key="year">2005</infon><infon key="source">Am J Hypertens</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>38496</offset><text>Increase of serum angiopoietin-2 during pregnancy is suppressed in women with preeclampsia</text><annotation id="20647"><infon key="identifier">285</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">22401</infon><location offset="38514" length="14" /><text>angiopoietin-2</text></annotation></passage><passage><infon key="volume">28</infon><infon key="section_type">REF</infon><infon key="fpage">1592</infon><infon key="pub-id_doi">10.1101/gad.237677.114</infon><infon key="pub-id_pmid">25030698</infon><infon key="year">2014</infon><infon key="source">Genes Dev</infon><infon key="type">ref</infon><infon key="lpage">603</infon><offset>38587</offset><text>Angiopoietin 2 regulates the transformation and integrity of lymphatic endothelial cell junctions</text></passage><passage><infon key="volume">18</infon><infon key="section_type">REF</infon><infon key="fpage">2382</infon><infon key="pub-id_doi">10.1158/1078-0432.CCR-11-2303</infon><infon key="pub-id_pmid">22351697</infon><infon key="year">2012</infon><infon key="source">Clin Cancer Res</infon><infon key="type">ref</infon><infon key="lpage">90</infon><offset>38685</offset><text>Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment</text></passage><passage><infon key="volume">17</infon><infon key="section_type">REF</infon><infon key="fpage">288</infon><infon key="pub-id_doi">10.1089/lrb.2017.0083</infon><infon key="pub-id_pmid">30358483</infon><infon key="year">2019</infon><infon key="source">Lymphat Res Biol</infon><infon key="type">ref</infon><infon key="lpage">93</infon><offset>38780</offset><text>Breast cancer-related lymphedema and genetic predisposition: a systematic review of the literature</text></passage><passage><infon key="volume">378</infon><infon key="section_type">REF</infon><infon key="fpage">2047</infon><infon key="pub-id_doi">10.1056/NEJMc1802399</infon><infon key="pub-id_pmid">29791815</infon><infon key="year">2018</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="lpage">8</infon><offset>38879</offset><text>Incidence of cellulitis among children with primary lymphedema</text></passage><passage><infon key="volume">87</infon><infon key="section_type">REF</infon><infon key="fpage">1181</infon><infon key="pub-id_doi">10.1016/S0092-8674(00)81814-0</infon><infon key="pub-id_pmid">8980225</infon><infon key="year">1996</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="lpage">90</infon><offset>38942</offset><text>Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase Tie2</text><annotation id="20648"><infon key="identifier">7294</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">2497</infon><location offset="39017" length="15" /><text>tyrosine kinase</text></annotation></passage><passage><infon key="volume">41</infon><infon key="section_type">REF</infon><infon key="fpage">118</infon><infon key="pub-id_doi">10.1038/ng.272</infon><infon key="pub-id_pmid">19079259</infon><infon key="year">2009</infon><infon key="source">Nat Genet</infon><infon key="type">ref</infon><infon key="lpage">24</infon><offset>39038</offset><text>Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations</text><annotation id="20649"><infon key="identifier">21687</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="39086" length="3" /><text>TEK</text></annotation></passage><passage><infon key="volume">125</infon><infon key="section_type">REF</infon><infon key="fpage">3491</infon><infon key="pub-id_doi">10.1172/JCI76004</infon><infon key="pub-id_pmid">26258417</infon><infon key="year">2015</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="lpage">504</infon><offset>39148</offset><text>Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects</text><annotation id="20650"><infon key="identifier">7010</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="39167" length="4" /><text>TIE2</text></annotation></passage><passage><infon key="volume">126</infon><infon key="section_type">REF</infon><infon key="fpage">2575</infon><infon key="pub-id_doi">10.1172/JCI85830</infon><infon key="pub-id_pmid">27270174</infon><infon key="year">2016</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="lpage">87</infon><offset>39235</offset><text>Angiopoietin receptor TEK mutations underlie primary congenital glaucoma with variable expressivity</text><annotation id="20651"><infon key="identifier">21687</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="39257" length="3" /><text>TEK</text></annotation></passage><passage><infon key="volume">127</infon><infon key="section_type">REF</infon><infon key="fpage">4421</infon><infon key="pub-id_doi">10.1172/JCI95545</infon><infon key="pub-id_pmid">29106382</infon><infon key="year">2017</infon><infon key="source">J Clin Invest</infon><infon key="type">ref</infon><infon key="lpage">36</infon><offset>39335</offset><text>Angiopoietin-1 is required for Schlemm's canal development in mice and humans</text><annotation id="20652"><infon key="identifier">284</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37447</infon><location offset="39335" length="14" /><text>Angiopoietin-1</text></annotation></passage><passage><infon key="volume">141</infon><infon key="section_type">REF</infon><infon key="fpage">1009</infon><infon key="pub-id_doi">10.1016/j.jaci.2017.05.020</infon><infon key="pub-id_pmid">28601681</infon><infon key="year">2018</infon><infon key="source">J Allergy Clin Immunol</infon><infon key="type">ref</infon><infon key="lpage">17</infon><offset>39413</offset><text>Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema</text><annotation id="20653"><infon key="identifier">284</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37447</infon><location offset="39450" length="6" /><text>ANGPT1</text></annotation><annotation id="20654"><infon key="identifier">284</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37447</infon><location offset="39429" length="14" /><text>angiopoietin-1</text></annotation></passage><passage><infon key="volume">87</infon><infon key="section_type">REF</infon><infon key="fpage">1171</infon><infon key="pub-id_doi">10.1016/S0092-8674(00)81813-9</infon><infon key="pub-id_pmid">8980224</infon><infon key="year">1996</infon><infon key="source">Cell</infon><infon key="type">ref</infon><infon key="lpage">80</infon><offset>39510</offset><text>Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis</text><annotation id="20655"><infon key="identifier">7010</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">397</infon><location offset="39561" length="4" /><text>Tie2</text></annotation><annotation id="20656"><infon key="identifier">284</infon><infon key="type">Gene</infon><infon key="NCBI Homologene">37447</infon><location offset="39528" length="14" /><text>angiopoietin-1</text></annotation></passage><passage><infon key="volume">376</infon><infon key="section_type">REF</infon><infon key="fpage">70</infon><infon key="pub-id_doi">10.1038/376070a0</infon><infon key="pub-id_pmid">7596437</infon><infon key="year">1995</infon><infon key="source">Nature</infon><infon key="type">ref</infon><infon key="lpage">4</infon><offset>39606</offset><text>Distinct roles of the receptor tyrosine kinases TIE-1 and Tie-2 in blood vessel formation</text></passage><relation id="R1"><infon key="score">0.9997</infon><infon key="role1">Disease|MESH:D008206</infon><infon key="role2">Gene|11601</infon><infon key="type">Association</infon></relation><relation id="R2"><infon key="score">0.9688</infon><infon key="role1">Gene|285</infon><infon key="role2">Gene|7294</infon><infon key="type">Bind</infon></relation><relation id="R3"><infon key="score">0.9935</infon><infon key="role1">DNAMutation|HGVS:g.6385085T&gt;C;CorrespondingGene:285</infon><infon key="role2">Disease|MESH:D010538</infon><infon key="type">Positive_Correlation</infon></relation><relation id="R4"><infon key="score">0.9921</infon><infon key="role1">DNAMutation|HGVS:c.557A&gt;G;CorrespondingGene:285</infon><infon key="role2">Disease|MESH:D015160</infon><infon key="type">Positive_Correlation</infon></relation><relation id="R5"><infon key="score">0.9474</infon><infon key="role1">DNAMutation|HGVS:c.557A&gt;G;CorrespondingGene:285</infon><infon key="role2">Disease|MESH:D010538</infon><infon key="type">Positive_Correlation</infon></relation><relation id="R6"><infon key="score">0.9917</infon><infon key="role1">DNAMutation|HGVS:g.6385085T&gt;C;CorrespondingGene:285</infon><infon key="role2">Disease|MESH:D015160</infon><infon key="type">Positive_Correlation</infon></relation><relation id="R7"><infon key="score">0.9994</infon><infon key="role1">Disease|MESH:D015160</infon><infon key="role2">Gene|285</infon><infon key="type">Association</infon></relation><relation id="R8"><infon key="score">0.9921</infon><infon key="role1">Disease|MESH:D015160</infon><infon key="role2">Gene|285</infon><infon key="type">Association</infon></relation><relation id="R9"><infon key="score">0.5871</infon><infon key="role1">Gene|285</infon><infon key="role2">Gene|7075</infon><infon key="type">Bind</infon></relation><relation id="R10"><infon key="score">0.9935</infon><infon key="role1">Disease|MESH:D010538</infon><infon key="role2">Gene|285</infon><infon key="type">Association</infon></relation><relation id="R11"><infon key="score">0.8559</infon><infon key="role1">Gene|285</infon><infon key="role2">Gene|7010</infon><infon key="type">Bind</infon></relation><relation id="R12"><infon key="score">0.9996</infon><infon key="role1">Disease|MESH:D010538</infon><infon key="role2">Gene|285</infon><infon key="type">Association</infon></relation></document>
</collection>